Details of Disease

General Information of Disease (ID: DIS48YMM)

• Disease Name: Thyroid gland papillary carcinoma
• Synonyms: thyroid gland papillary carcinoma; thyroid papillary carcinoma; papillary carcinoma of thyroid; papillary cancer of thyroid gland; papillary carcinoma of the thyroid; papillary cancer of the thyroid; papillary cancer of thyroid; papillary cancer of the thyroid gland; thyroid gland papillary cancer; papillary thyroid carcinoma; papillary thyroid cancer; papillary carcinoma of the thyroid gland; papillary thyroid gland carcinoma; papillary carcinoma of thyroid gland
• Definition: A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries. Diagnostic procedures include thyroid ultrasound and fine needle biopsy. Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei. The nuclei also display clearing or have a ground glass appearance.
• Disease Hierarchy:
  DISC68C7: Papillary adenocarcinoma
  DIS1V20Y: Differentiated thyroid carcinoma
  DISEZVFP: Thyroid gland adenocarcinoma
  DIS48YMM: Thyroid gland papillary carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0005075
  MESH ID: D000077273
  UMLS CUI: C0238463
  MedGen ID: 66773
  HPO ID: HP:0002895
  SNOMED CT ID: 255029007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lenvatinib	DMB1IU4	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 182 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADAMTS1	TTS2TEI	Limited	Altered Expression	[2]
ADCY1	TTV1ZSQ	Limited	Altered Expression	[3]
ADCYAP1R1	TT5OREU	Limited	Altered Expression	[4]
AMACR	TTLN1AP	Limited	Genetic Variation	[5]
APOL1	TTDB8PW	Limited	Biomarker	[6]
ARAF	TT5TURO	Limited	Altered Expression	[7]
CASP2	TT12VNG	Limited	Biomarker	[8]
CD1A	TTBGTFN	Limited	Biomarker	[9]
CDK8	TTBJR4L	Limited	Biomarker	[10]
CRY2	TTAO58M	Limited	Altered Expression	[11]
CSNK1G2	TT0UZJ9	Limited	Genetic Variation	[12]
DCK	TTJOCE4	Limited	Biomarker	[13]
ECE1	TTQ9RYT	Limited	Biomarker	[14]
EML4	TT92GY4	Limited	Genetic Variation	[15]
ENPP2	TTSCIM2	Limited	Altered Expression	[16]
EPHB3	TT5LM7U	Limited	Biomarker	[17]
EZH1	TTNJA0C	Limited	Genetic Variation	[18]
FCER2	TTCH6MU	Limited	Altered Expression	[19]
FPR2	TTOJ1NF	Limited	Genetic Variation	[20]
GLA	TTIS03D	Limited	Altered Expression	[21]
GPI	TT19JIZ	Limited	Altered Expression	[22]
HBB	TTM6HK1	Limited	Genetic Variation	[23]
HMGB2	TTA78JQ	Limited	Biomarker	[24]
HRAS	TT28ZON	Limited	SomaticCausalMutation	[25]
HSP90AB1	TTH5YN2	Limited	Altered Expression	[26]
HTRA1	TT8POQR	Limited	Altered Expression	[27]
IL11RA	TTZPLJS	Limited	Genetic Variation	[28]
KCNJ2	TTH7UO3	Limited	Altered Expression	[29]
KSR1	TTHL1TV	Limited	Altered Expression	[30]
LAIR1	TTSI7A8	Limited	Biomarker	[31]
MCM7	TT1RM3F	Limited	Altered Expression	[32]
MMP11	TTZW4MV	Limited	Altered Expression	[33]
MTF1	TTTQDEO	Limited	Biomarker	[34]
PAK4	TT7Y3BZ	Limited	Biomarker	[35]
PARG	TT39J16	Limited	Genetic Variation	[36]
PDGFC	TTOABM9	Limited	Altered Expression	[37]
PHGDH	TT8DRCK	Limited	Altered Expression	[38]
PLD2	TTRLMKF	Limited	Altered Expression	[39]
PRKACA	TT5U49F	Limited	Altered Expression	[35]
PRKCE	TT57MT2	Limited	Altered Expression	[40]
PRLR	TTBPXMA	Limited	Altered Expression	[41]
PTGIS	TTLXKZR	Limited	Biomarker	[42]
PTPRJ	TTWMKXP	Limited	Genetic Variation	[43]
QPCT	TTJ7YTV	Limited	Altered Expression	[44]
RAPGEF3	TTOE7I0	Limited	Altered Expression	[45]
ROR2	TTUDPCI	Limited	Biomarker	[46]
RSPO1	TTI9HL4	Limited	Altered Expression	[47]
RXRG	TTH029C	Limited	Biomarker	[48]
SERPINB5	TT1KW50	Limited	Posttranslational Modification	[49]
SLC26A4	TT7X02I	Limited	Genetic Variation	[50]
SLC6A9	TTHJTF7	Limited	Biomarker	[51]
SP1	TTZEP6S	Limited	Altered Expression	[52]
TAGLN2	TTP6BIJ	Limited	Biomarker	[53]
TK1	TTP3QRF	Limited	Biomarker	[13]
TKTL1	TTNQ1J3	Limited	Altered Expression	[54]
TLR6	TTWRI8V	Limited	Genetic Variation	[55]
TSG101	TTHU7JA	Limited	Altered Expression	[56]
TUSC2	TTJ8O14	Limited	Altered Expression	[57]
UGCG	TTPHEX3	Limited	Altered Expression	[58]
UTS2R	TTW5UDX	Limited	Biomarker	[59]
WNT7A	TT8NARC	Limited	Biomarker	[60]
APOA4	TTNC3WS	Disputed	Biomarker	[61]
CFD	TT8D13I	Disputed	Biomarker	[62]
CXCL11	TTWG0RE	Disputed	Biomarker	[63]
FGF19	TTGCH11	Disputed	Biomarker	[64]
HLA-G	TTLKFB3	Disputed	Biomarker	[59]
MAGEA2	TTOZT28	Disputed	Biomarker	[65]
MOG	TTQAFX5	Disputed	Biomarker	[66]
PINX1	TT4FJ3A	Disputed	Biomarker	[67]
CCR7	TT2GIDQ	moderate	Altered Expression	[68]
CUL3	TTPCU0Q	moderate	Biomarker	[69]
DIO1	TTU3X26	moderate	Biomarker	[70]
DKK1	TTE3RAC	moderate	Altered Expression	[71]
KLK7	TTE6GTB	moderate	Altered Expression	[72]
MAPKAP1	TTWDKCL	moderate	Altered Expression	[73]
RPE65	TTBOH16	moderate	Biomarker	[74]
SIRT6	TTUXYWF	moderate	Biomarker	[75]
SPHK2	TTCN0M9	moderate	Altered Expression	[76]
STOML2	TTOI329	moderate	Biomarker	[77]
VEGFD	TTOM5H4	moderate	Altered Expression	[78]
WNT5A	TTKG7F8	moderate	Altered Expression	[79]
AGK	TTJETQC	Strong	Biomarker	[80]
AKT3	TTO6SGY	Strong	Biomarker	[81]
ALK	TTPMQSO	Strong	Biomarker	[82]
CA12	TTSYM0R	Strong	Biomarker	[83]
CASP6	TTKW4ML	Strong	Altered Expression	[84]
CCL21	TTLZK1U	Strong	Biomarker	[68]
CDH6	TT9QHUK	Strong	Altered Expression	[85]
CHEK2	TT9ABMF	Strong	Altered Expression	[86]
CTSC	TT4H0V2	Strong	Altered Expression	[87]
CXCL12	TT4UGTF	Strong	Biomarker	[88]
CXXC5	TTVS4C3	Strong	Altered Expression	[89]
CYP24A1	TT82UI1	Strong	Biomarker	[90]
DCN	TTB3XAN	Strong	Biomarker	[83]
DDR2	TTU98HG	Strong	Altered Expression	[91]
DICER1	TTTEOPU	Strong	Altered Expression	[92]
DPP4	TTDIGC1	Strong	Biomarker	[93]
DUSP5	TTZN92A	Strong	Altered Expression	[94]
EBP	TT4VQZX	Strong	Altered Expression	[95]
FLT3	TTGJCWZ	Strong	Biomarker	[96]
FOXQ1	TTEJZOL	Strong	Altered Expression	[97]
GABRB2	TTZA1NY	Strong	Biomarker	[98]
GCGR	TT9O6WS	Strong	Altered Expression	[99]
GPRC6A	TTI1PRE	Strong	Genetic Variation	[100]
HIPK2	TTOB49C	Strong	Biomarker	[101]
HMBS	TTT0HW3	Strong	Genetic Variation	[102]
IGFBP5	TTDWEA8	Strong	Altered Expression	[103]
IL13RA2	TTMPZ7V	Strong	Altered Expression	[104]
IRAK1	TTXAJWN	Strong	Genetic Variation	[105]
ITCH	TT5SEWD	Strong	Altered Expression	[106]
ITGA2	TTSJ542	Strong	Altered Expression	[107]
ITGA5	TTHIZP9	Strong	Biomarker	[107]
KDM1A	TTNR0UQ	Strong	Biomarker	[108]
KLB	TTARBVH	Strong	Altered Expression	[109]
KRAS	TTM8FR7	Strong	Genetic Variation	[110]
KRT19	TT3JF9E	Strong	Biomarker	[111]
LAMB3	TT2WOUQ	Strong	Biomarker	[112]
LGR4	TTY6C71	Strong	Biomarker	[113]
LPAR3	TTE2YJR	Strong	Genetic Variation	[114]
LPAR4	TT7ZMY4	Strong	SomaticCausalMutation	[115]
LRRC32	TT0FAYT	Strong	Altered Expression	[116]
MAP2K7	TT6QY3J	Strong	Genetic Variation	[117]
MAP4K3	TTI0AHJ	Strong	Biomarker	[118]
MDK	TTV8UE7	Strong	Biomarker	[119]
MRGPRX1	TTIX6PK	Strong	Genetic Variation	[100]
MTDH	TTH6SA5	Strong	Altered Expression	[120]
MUC1	TTBHFYQ	Strong	Altered Expression	[121]
NCAM1	TTVXPHT	Strong	Biomarker	[122]
NCOA4	TT8OY02	Strong	Genetic Variation	[123]
NDUFA13	TTRU1NG	Strong	SomaticCausalMutation	[124]
NECTIN4	TTPO9EG	Strong	Biomarker	[125]
NRAS	TTW2R9X	Strong	Genetic Variation	[126]
NRG1	TTEH395	Strong	Genetic Variation	[127]
NTRK1	TTTDVOJ	Strong	Altered Expression	[123]
NTRK3	TTXABCW	Strong	Genetic Variation	[128]
OGFR	TT6IEYX	Strong	Biomarker	[129]
OSMR	TTAH0KM	Strong	Biomarker	[130]
OXER1	TT7WBSV	Strong	Genetic Variation	[100]
PDGFRA	TT8FYO9	Strong	Biomarker	[131]
PDPK1	TTYMGWX	Strong	Altered Expression	[132]
PPARG	TTT2SVW	Strong	FusionGene	[133]
PTN	TTA9EJK	Strong	Biomarker	[134]
RACK1	TTJ10AL	Strong	Altered Expression	[135]
RARA	TTW38KT	Strong	Altered Expression	[136]
RARG	TT1Q3IE	Strong	Altered Expression	[136]
RGS4	TTGTKX9	Strong	Biomarker	[137]
ROCK1	TTZN7RP	Strong	Altered Expression	[138]
RUNX2	TTD6SZ8	Strong	Biomarker	[139]
S100A4	TTPR5SX	Strong	Biomarker	[140]
S100A6	TT716MY	Strong	Altered Expression	[141]
SELL	TT2IYXF	Strong	Altered Expression	[2]
SERPINB3	TT6QLPX	Strong	Altered Expression	[142]
SLC5A5	TTW7HI9	Strong	Altered Expression	[143]
SPHK1	TTOHFIY	Strong	Altered Expression	[144]
TACSTD2	TTP2HE5	Strong	Biomarker	[77]
THBS1	TTKI0H1	Strong	Altered Expression	[145]
THRB	TTGER3L	Strong	Altered Expression	[146]
TIGIT	TTWNL74	Strong	Biomarker	[147]
TOP2A	TTCGY2K	Strong	Biomarker	[148]
TPO	TT52XDZ	Strong	Biomarker	[149]
TRIM24	TT9Q7AE	Strong	FusionGene	[150]
TRIM27	TTTO3QN	Strong	FusionGene	[150]
TRPM3	TTO3TD8	Strong	Altered Expression	[151]
VEGFC	TT0QUFV	Strong	Altered Expression	[152]
ZEB2	TTT2WK4	Strong	Biomarker	[153]
ATAD2	TT9A0HI	Definitive	Altered Expression	[154]
CBL	TT7QT13	Definitive	Altered Expression	[106]
CDK7	TTQYF7G	Definitive	Altered Expression	[155]
CRLF1	TT6YF5K	Definitive	Altered Expression	[156]
ERAP2	TTVGS1C	Definitive	Altered Expression	[87]
GAP43	TTSGLN5	Definitive	Biomarker	[157]
GPNMB	TT7315J	Definitive	Altered Expression	[87]
KMT5A	TTGC95K	Definitive	Biomarker	[158]
LASP1	TTZJA87	Definitive	Biomarker	[159]
MAP3K14	TT4LIAC	Definitive	Altered Expression	[160]
MS4A1	TTUE541	Definitive	Altered Expression	[161]
PBK	TTMY6BZ	Definitive	Altered Expression	[160]
SLC1A5	TTF7WRM	Definitive	Biomarker	[162]
SLC7A11	TTBZMIO	Definitive	Biomarker	[163]
SMYD2	TT7YJFO	Definitive	Altered Expression	[164]
USP33	TT4E85Q	Definitive	Biomarker	[165]
WDR5	TT7OFWB	Definitive	Altered Expression	[166]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC16A2	DTQ8MP1	Limited	Biomarker	[167]
SLC5A8	DTE3TAW	Strong	Genetic Variation	[168]

This Disease Is Related to 9 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
DHRS3	DEXPVUN	Limited	Biomarker	[169]
PGPEP1	DEVDR46	Limited	Biomarker	[42]
MT1A	DE5ME8A	moderate	Altered Expression	[170]
CYP27B1	DE3FYEM	Strong	Altered Expression	[171]
CYP2R1	DEBIHM3	Strong	Genetic Variation	[172]
NNMT	DECVGJ3	Strong	Altered Expression	[173]
WARS1	DEPVE0M	Strong	Biomarker	[153]
AKR1C2	DEOY5ZM	Definitive	Altered Expression	[174]
PGM1	DEA3VM1	Definitive	Altered Expression	[175]

This Disease Is Related to 333 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACBD5	OT7L16DY	Limited	Biomarker	[5]
ADAT2	OT8AG6ZN	Limited	Altered Expression	[176]
AFAP1L2	OTJBI0VN	Limited	Biomarker	[177]
AFM	OTPOR8IO	Limited	Biomarker	[178]
AHNAK2	OTD2X4BX	Limited	Biomarker	[53]
AKAP13	OTOZAR14	Limited	Biomarker	[179]
ANKRD36B	OT3MW415	Limited	Altered Expression	[180]
ANO5	OTOW8R6H	Limited	Altered Expression	[181]
APC	OTKV0TIK	Limited	Genetic Variation	[182]
B4GALNT3	OT6BFB22	Limited	Genetic Variation	[183]
BMPR1A	OTQOA4ZH	Limited	Genetic Variation	[184]
BUB3	OTU91HAU	Limited	Genetic Variation	[185]
CCNA1	OTX4HD45	Limited	Altered Expression	[186]
CD207	OTI9RUDN	Limited	Biomarker	[9]
CDC45	OT6NNLOD	Limited	Biomarker	[187]
CHFR	OTRAD2TT	Limited	Biomarker	[70]
CHL1	OT6E6E8P	Limited	Biomarker	[188]
CKS2	OTPTMHIV	Limited	Altered Expression	[189]
CLDN16	OTTHAIKR	Limited	Altered Expression	[190]
CLPTM1L	OTDJWQXI	Limited	Genetic Variation	[191]
CPT1C	OT8F1MBF	Limited	Altered Expression	[192]
CRKL	OTOYSD1R	Limited	Altered Expression	[193]
CROT	OTWK68MM	Limited	Altered Expression	[194]
CTNNA1	OTFC725Z	Limited	Genetic Variation	[2]
DCSTAMP	OTFKRP2H	Limited	Biomarker	[195]
DCT	OTYVNTBG	Limited	Genetic Variation	[196]
DUOX1	OTQ2AEW0	Limited	Biomarker	[197]
DUOX2	OTU14HCN	Limited	Altered Expression	[197]
DUSP2	OTH54FMR	Limited	Altered Expression	[4]
E2F4	OTB3JFH4	Limited	Biomarker	[198]
ECRG4	OTHZYUXX	Limited	Genetic Variation	[199]
EGR2	OTAVQ78J	Limited	Biomarker	[200]
EHD2	OTTX391J	Limited	Altered Expression	[201]
EHF	OTY6TPWD	Limited	Altered Expression	[202]
EIF4EBP3	OTYY2WS5	Limited	Genetic Variation	[179]
EMSY	OTBQ3KQE	Limited	Biomarker	[203]
FRS2	OTDMD800	Limited	Biomarker	[204]
FUCA1	OTW71IK4	Limited	Altered Expression	[205]
FXYD5	OT81DIOD	Limited	Altered Expression	[206]
FZD1	OTZATHVS	Limited	Biomarker	[207]
GAGE1	OT53E50E	Limited	Altered Expression	[208]
GAGE4	OTPB5C0O	Limited	Altered Expression	[208]
GAGE5	OTFI6OVS	Limited	Altered Expression	[208]
GDE1	OTU6FSBF	Limited	Biomarker	[209]
HABP2	OTAUIPW0	Limited	Genetic Variation	[110]
HOOK3	OT0OE8SX	Limited	Genetic Variation	[210]
HSPA14	OTZCA5LK	Limited	Altered Expression	[211]
HTRA3	OTXJ0H4X	Limited	Altered Expression	[27]
HUS1	OTY1XON9	Limited	Genetic Variation	[212]
IL17RA	OTVVI8ER	Limited	Genetic Variation	[213]
IL17RB	OT0KDNSF	Limited	Genetic Variation	[213]
IL22RA1	OTGVKLBR	Limited	Biomarker	[214]
IQGAP1	OTZRWTGA	Limited	Genetic Variation	[215]
KAZN	OTPM7BYM	Limited	Altered Expression	[216]
KLF17	OT5NWVP7	Limited	Altered Expression	[217]
LAT	OTZC1XZ1	Limited	Biomarker	[218]
LBR	OT1HG3HG	Limited	Altered Expression	[219]
LDOC1	OTWZH4O9	Limited	Altered Expression	[220]
LOXL1	OTA0NEJU	Limited	Genetic Variation	[70]
MARK1	OTP7KL47	Limited	Genetic Variation	[221]
MBIP	OTORHZ9Y	Limited	Altered Expression	[222]
MCM3	OTOOHQPM	Limited	Altered Expression	[223]
MMUT	OTBBBV70	Limited	Biomarker	[224]
MPPED2	OT7XLMJ6	Limited	Biomarker	[225]
MRPL41	OTG5URO4	Limited	Biomarker	[226]
MRPL44	OT27ZC26	Limited	Altered Expression	[227]
MT1E	OTXJKU4Y	Limited	Biomarker	[170]
MT1F	OTZVUYG1	Limited	Biomarker	[170]
MZB1	OT071TET	Limited	Altered Expression	[4]
NAA10	OTYB9R6I	Limited	Biomarker	[228]
NAA15	OT53SIZG	Limited	Altered Expression	[229]
NCOA5	OTOGWTWB	Limited	Altered Expression	[230]
NRARP	OTMYHUV2	Limited	Biomarker	[231]
NT5C1A	OTS7UF36	Limited	Biomarker	[232]
PIWIL2	OT1PXQIF	Limited	Altered Expression	[233]
POU5F1B	OT0FKQ51	Limited	Genetic Variation	[234]
PRAP1	OT48QD82	Limited	Altered Expression	[235]
PRDX6	OTS8KC8A	Limited	Biomarker	[236]
PSG1	OT1U4ZZW	Limited	Altered Expression	[200]
PSMD8	OTY6X27P	Limited	Altered Expression	[237]
PSMG1	OTZ5I6UM	Limited	Altered Expression	[4]
RAB23	OTBAKFBR	Limited	Genetic Variation	[12]
RAB40B	OTCA9ZF5	Limited	Altered Expression	[238]
RAP1GAP	OTC31ONQ	Limited	Altered Expression	[239]
RASGRP3	OTEMEV3P	Limited	Biomarker	[240]
RBMX	OTFZN66E	Limited	Biomarker	[241]
RBP2	OTR8QG5V	Limited	Biomarker	[242]
RMDN1	OTE1NB6U	Limited	Biomarker	[243]
RMDN2	OTK5WSFI	Limited	Biomarker	[243]
RMDN3	OTKO7AUM	Limited	Biomarker	[243]
RNASE2	OT8Z4FNE	Limited	Biomarker	[244]
RPIA	OT805SMH	Limited	Biomarker	[245]
S100A13	OT582SUS	Limited	Biomarker	[141]
SART3	OTC1AM7S	Limited	Genetic Variation	[246]
SCEL	OT46SDNQ	Limited	Biomarker	[247]
SDHB	OTRE1M1T	Limited	Biomarker	[248]
SERP1	OT60XXUP	Limited	Biomarker	[244]
SERPINA5	OTTZXPGD	Limited	Genetic Variation	[249]
SERPINE2	OTYF5340	Limited	Biomarker	[250]
SHMT1	OTIINA3J	Limited	Altered Expression	[38]
SKA1	OTDYJ12A	Limited	Biomarker	[251]
SLC35F2	OTSAD4EQ	Limited	Biomarker	[252]
SMG1	OTTS3SXE	Limited	Altered Expression	[16]
SNX5	OT6ZOWMU	Limited	Altered Expression	[8]
SRRM2	OTSIMMC9	Limited	Genetic Variation	[253]
STK17B	OT4NYNO8	Limited	Biomarker	[254]
STUB1	OTSUYI9A	Limited	Biomarker	[255]
SYBU	OT3FQV7N	Limited	Biomarker	[243]
TFCP2L1	OT7QIJ0X	Limited	Biomarker	[29]
TINF2	OT861N2N	Limited	Autosomal dominant	[256]
TLR10	OTQ1KVJO	Limited	Genetic Variation	[55]
TMEM50B	OTWJK2XZ	Limited	Genetic Variation	[257]
TP53I3	OTSCM68G	Limited	Biomarker	[226]
TRAK2	OTXVA7FN	Limited	Genetic Variation	[179]
TRIM44	OT0B1T2B	Limited	Biomarker	[258]
CCT3	OTL6EOS1	Disputed	Altered Expression	[259]
CD247	OT45FGUX	Disputed	Biomarker	[260]
CDC14B	OTAESVOZ	Disputed	Biomarker	[261]
CERS1	OT6EYRM3	Disputed	Biomarker	[262]
CERS2	OTRAHYYP	Disputed	Altered Expression	[262]
E2F6	OT2PN28R	Disputed	Altered Expression	[263]
E2F8	OTQKZGFP	Disputed	Altered Expression	[264]
GRK6	OT4LZTP9	Disputed	Altered Expression	[265]
KHSRP	OTDHZARB	Disputed	Altered Expression	[266]
LMO7	OTDLY6TC	Disputed	Genetic Variation	[267]
MAL2	OTVPEI80	Disputed	Biomarker	[268]
NAALADL1	OTQNOZBP	Disputed	Biomarker	[269]
NNAT	OTNRLO7G	Disputed	Altered Expression	[261]
RASSF10	OTGB7EBG	Disputed	Altered Expression	[270]
SOD3	OTIOZQAB	Disputed	Altered Expression	[271]
TAS2R3	OTX8ZG2D	Disputed	Genetic Variation	[272]
TCIM	OTARUXQF	Disputed	Biomarker	[273]
TNRC6C	OTBR07PM	Disputed	Altered Expression	[274]
TRIM8	OTS6JFR0	Disputed	Biomarker	[275]
ATP5F1E	OTMPLAIS	moderate	Altered Expression	[276]
BCAM	OTHZOPSD	moderate	Altered Expression	[277]
CCDC80	OTOZSYEM	moderate	Altered Expression	[278]
CKAP4	OTDUC9ME	moderate	Biomarker	[74]
DIO2	OTGPNSLH	moderate	Altered Expression	[279]
HOXD13	OTWSC8TF	moderate	Altered Expression	[280]
PDCD4	OTZ6NXUX	moderate	Altered Expression	[281]
PPP1R13L	OTNCPLWE	moderate	Biomarker	[282]
PROX1	OT68R6IO	moderate	Altered Expression	[283]
RBX1	OTYA1UIO	moderate	Biomarker	[69]
RNH1	OT6EC79B	moderate	Biomarker	[282]
RTN4IP1	OTHUZANE	moderate	Altered Expression	[284]
SGSM3	OTIB1P8A	moderate	Genetic Variation	[285]
SHC3	OT305NPA	moderate	Biomarker	[282]
SOX17	OT9H4WWE	moderate	Altered Expression	[286]
SYTL2	OTUIOWKL	moderate	Biomarker	[77]
TTF2	OT5LJOWM	moderate	Genetic Variation	[287]
AKAP9	OT7Z2YRP	Strong	Biomarker	[288]
AMFR	OTQRX7LC	Strong	Altered Expression	[22]
ARFGEF1	OTPAU0L4	Strong	Biomarker	[289]
ATF1	OT251CI0	Strong	Altered Expression	[290]
BEGAIN	OTT3UD2K	Strong	Biomarker	[153]
BTRC	OT2EZDGR	Strong	Altered Expression	[291]
CD63	OT2UGZA9	Strong	Genetic Variation	[292]
CDC23	OTC4O83E	Strong	Altered Expression	[293]
CENPJ	OTZCQZN5	Strong	Biomarker	[294]
CIB1	OT4BVCRU	Strong	Biomarker	[295]
CISH	OT8T5NYL	Strong	Altered Expression	[296]
CITED1	OTUJQ3VL	Strong	Altered Expression	[297]
CLDN1	OT27KV99	Strong	Biomarker	[298]
CLDN10	OT2CVAKY	Strong	Altered Expression	[299]
CLIP2	OTSCIQIY	Strong	Biomarker	[300]
CNGB1	OTA5DE38	Strong	Altered Expression	[116]
CPSF2	OTU6QXZE	Strong	Altered Expression	[301]
CRABP1	OTISDG5X	Strong	Biomarker	[302]
CUX2	OTDJTQAJ	Strong	Biomarker	[303]
CXCL14	OTM189TA	Strong	Biomarker	[304]
DACT2	OTNLCC0K	Strong	Posttranslational Modification	[305]
DEUP1	OTXLM86J	Strong	Biomarker	[306]
DPT	OTINRFC7	Strong	Biomarker	[307]
DUSP6	OT4H6RKW	Strong	Biomarker	[308]
DYNC1H1	OTD1KRKO	Strong	Biomarker	[153]
EIF1AX	OTWG2LAB	Strong	Genetic Variation	[309]
ELF3	OTUTLEQO	Strong	Altered Expression	[310]
ERC1	OTYBGGNO	Strong	Biomarker	[311]
ETV5	OTE2OBM4	Strong	Biomarker	[312]
ETV6	OTCZMG61	Strong	Genetic Variation	[128]
FAM83F	OTGGJRO7	Strong	Biomarker	[313]
FOXE1	OT5IR5IT	Strong	Altered Expression	[314]
GABPA	OT9YB2SA	Strong	Biomarker	[315]
GAS1	OTKJXG52	Strong	Altered Expression	[316]
GDF1	OTZ1VRBH	Strong	Biomarker	[282]
GLIS3	OTBC960E	Strong	Biomarker	[317]
GOLGA5	OTG6HB6U	Strong	FusionGene	[150]
GPR151	OT7EACU6	Strong	Genetic Variation	[100]
HOPX	OTBSR6C9	Strong	Altered Expression	[318]
HOXA3	OTIX5XFB	Strong	Biomarker	[319]
IHH	OT1DWGXC	Strong	Altered Expression	[320]
ITGA3	OTBCH21D	Strong	Biomarker	[321]
IYD	OT8BQWTE	Strong	Altered Expression	[322]
KIDINS220	OTLBH2MA	Strong	Genetic Variation	[323]
KIF5B	OTT34MT8	Strong	Biomarker	[324]
KLK10	OTD573EL	Strong	Altered Expression	[325]
LIPH	OTRGYLKL	Strong	Altered Expression	[326]
LMO4	OT5NDCT9	Strong	Biomarker	[327]
LRP4	OTO4M459	Strong	Biomarker	[83]
MCM5	OTAHLB62	Strong	Altered Expression	[328]
MRGPRX3	OTRKCCDS	Strong	Genetic Variation	[100]
MRGPRX4	OTOBHZVA	Strong	Genetic Variation	[100]
MT1G	OTAV1OCR	Strong	Biomarker	[170]
MT1M	OTVT8PLU	Strong	Biomarker	[329]
MT1X	OT9AKFVS	Strong	Biomarker	[170]
NECTIN1	OTTE5ZR6	Strong	Altered Expression	[330]
NLRP6	OTEREN4W	Strong	Genetic Variation	[110]
NOB1	OTW0YNSL	Strong	Biomarker	[331]
NPC2	OTE9UEJC	Strong	Altered Expression	[332]
NRCAM	OT80HHQ2	Strong	Biomarker	[333]
NUCB2	OTHO6JWN	Strong	Biomarker	[334]
NUP93	OT4J2VAL	Strong	Genetic Variation	[110]
OPN1LW	OTFNUZ7O	Strong	Biomarker	[335]
PAG1	OTFOJUIQ	Strong	Biomarker	[335]
PC	OT6O0V51	Strong	Biomarker	[336]
PCBP4	OTDLL4NB	Strong	Biomarker	[335]
PCM1	OTFM133C	Strong	Biomarker	[337]
PDPN	OTBUV19I	Strong	Biomarker	[338]
PES1	OTMZK7XE	Strong	Biomarker	[339]
PJA2	OT45TMC4	Strong	Altered Expression	[340]
POLQ	OTBHK0E6	Strong	Altered Expression	[341]
POLR2E	OTH5IL2A	Strong	Genetic Variation	[342]
PPP2R5C	OTF7CGO2	Strong	Biomarker	[153]
PROK1	OT8S7RUG	Strong	Altered Expression	[343]
PROK2	OT70IFEZ	Strong	Biomarker	[343]
PRPF31	OTSJ0Z1Y	Strong	Genetic Variation	[148]
PSD4	OTEFB87Z	Strong	Altered Expression	[320]
PTCH2	OTOQ0K9V	Strong	Biomarker	[344]
RAD52	OT0OTDHI	Strong	Genetic Variation	[345]
RAPGEF5	OT53VS75	Strong	Genetic Variation	[346]
RASAL1	OTAHUNN7	Strong	Genetic Variation	[347]
RELCH	OTVGTXDB	Strong	Biomarker	[348]
REV1	OTHIKICX	Strong	Altered Expression	[349]
RSPO2	OT3HHXU0	Strong	Altered Expression	[113]
RUFY2	OTT9C6SM	Strong	Biomarker	[348]
S100A11	OTI57KDN	Strong	Altered Expression	[350]
SCAI	OTAK3TMO	Strong	Biomarker	[351]
SFTPB	OTOHS07E	Strong	Biomarker	[352]
SIRT7	OT5M4OT4	Strong	Biomarker	[353]
SNAI1	OTDPYAMC	Strong	Altered Expression	[354]
SNAI2	OT7Y8EJ2	Strong	Biomarker	[153]
SOX11	OT4LG7LA	Strong	Genetic Variation	[355]
SOX12	OT93P8C9	Strong	Altered Expression	[356]
SPINT1	OT1CLR5L	Strong	Altered Expression	[357]
SRF	OTW18FQN	Strong	Altered Expression	[358]
SRGAP1	OTL89HGW	Strong	Biomarker	[359]
STON2	OT01JHHE	Strong	Biomarker	[360]
TAB1	OTPM6F85	Strong	Biomarker	[361]
TENM1	OTSKSU4V	Strong	Altered Expression	[362]
TFF3	OTJJDRTU	Strong	Biomarker	[363]
TFG	OT2KJENI	Strong	Biomarker	[364]
TIMP1	OTOXC51H	Strong	Biomarker	[365]
TIMP3	OTDGQAD1	Strong	Altered Expression	[366]
TMSB10	OTLVZ13T	Strong	Altered Expression	[367]
TPM3	OT5RU5G6	Strong	Biomarker	[368]
TPR	OTUBBA4W	Strong	Genetic Variation	[369]
TRIM14	OTLQKUG0	Strong	Biomarker	[370]
TRIM26	OTS0DJIP	Strong	Altered Expression	[371]
TRIM33	OT0KS4J7	Strong	Altered Expression	[123]
TSPAN13	OTCS9BZY	Strong	Altered Expression	[372]
ABHD11	OTJE9UZY	Definitive	Altered Expression	[162]
AGRN	OTWJENAZ	Definitive	Altered Expression	[87]
AMPD1	OTU17BCI	Definitive	Biomarker	[373]
ANKRD26	OT2ENKKV	Definitive	Biomarker	[374]
AP2A1	OTEFZB21	Definitive	Biomarker	[375]
ATF7IP	OTU6ZA7F	Definitive	Biomarker	[376]
BEX3	OTW1V1L5	Definitive	Biomarker	[377]
BRMS1	OTV5A6LL	Definitive	Altered Expression	[378]
C6orf47	OTMKBNDD	Definitive	Genetic Variation	[379]
CAVIN2	OTFHHDRU	Definitive	Altered Expression	[380]
CCL4L2	OTDBSXOU	Definitive	Biomarker	[262]
CCNG1	OT17IA9L	Definitive	Biomarker	[381]
CDK15	OT8S67QS	Definitive	Altered Expression	[160]
CDK16	OTUBXIIT	Definitive	Altered Expression	[160]
CEMIP	OTK80FYN	Definitive	Biomarker	[382]
CILK1	OTWOYEYP	Definitive	Altered Expression	[160]
CNBP	OTTGM9NK	Definitive	Biomarker	[383]
COPS6	OTG9AAG0	Definitive	Altered Expression	[384]
CTNNBIP1	OTX9SBJG	Definitive	Altered Expression	[385]
DNM3	OTDMUGCR	Definitive	Altered Expression	[386]
DROSHA	OTCE68KZ	Definitive	Genetic Variation	[387]
E2F7	OTWW358N	Definitive	Biomarker	[388]
EHD1	OTDMEKLV	Definitive	Altered Expression	[389]
ELOVL2	OTDAF6U3	Definitive	Biomarker	[390]
EMX2	OT0V8OYK	Definitive	Biomarker	[391]
EPS15	OT7NPP8U	Definitive	Biomarker	[389]
ETV4	OT8C98UZ	Definitive	Biomarker	[392]
FLVCR1	OT9XCFOC	Definitive	Biomarker	[393]
FNDC5	OT5CSK9X	Definitive	Altered Expression	[394]
FOXF1	OT2CJZ5K	Definitive	Genetic Variation	[395]
GATAD2A	OTFM8D3O	Definitive	Biomarker	[396]
HCP5	OTV0YRI8	Definitive	Biomarker	[397]
HOXD10	OT0NOWU2	Definitive	Posttranslational Modification	[398]
HSDL2	OT4IN0MV	Definitive	Altered Expression	[399]
IMPACT	OTQ923OB	Definitive	Biomarker	[400]
INPPL1	OTCDAVBQ	Definitive	Biomarker	[401]
IWS1	OTF96EYX	Definitive	Biomarker	[402]
JAZF1	OTXTYSYD	Definitive	Altered Expression	[403]
LARP7	OTLLOZTL	Definitive	Altered Expression	[404]
LIMD2	OTSIFTD8	Definitive	Altered Expression	[405]
LMLN	OTQF0JPY	Definitive	Posttranslational Modification	[398]
LRIG1	OTY5HZN5	Definitive	Altered Expression	[406]
MRTFA	OTCVXASM	Definitive	Altered Expression	[407]
MYO1G	OTOCFS3Q	Definitive	Biomarker	[408]
OTUB2	OTZUMPH2	Definitive	Altered Expression	[409]
PAQR3	OTTKJ9Y4	Definitive	Altered Expression	[410]
PCNX2	OT90S9W6	Definitive	Genetic Variation	[411]
PKHD1L1	OTREFCAA	Definitive	Altered Expression	[412]
PLXNC1	OTJ5XKYY	Definitive	Biomarker	[413]
PRKACG	OTKOQYF8	Definitive	Altered Expression	[160]
PROSER3	OTOIA942	Definitive	Biomarker	[148]
PSME3	OTSTC4YY	Definitive	Biomarker	[414]
RAB11FIP3	OTDFFCZA	Definitive	Altered Expression	[389]
RRS1	OTTNCZN6	Definitive	Biomarker	[415]
SCOC	OTPJ3RQ4	Definitive	Biomarker	[416]
SDC4	OTKUVUGZ	Definitive	Altered Expression	[417]
SH3BGRL3	OTKMW34I	Definitive	Biomarker	[87]
SOCS2	OTBPNKJQ	Definitive	Biomarker	[296]
STRN	OTLOZL5I	Definitive	Genetic Variation	[418]
SYPL1	OTBX291E	Definitive	Biomarker	[416]
TBX3	OTM64N7K	Definitive	Biomarker	[419]
TCEAL9	OT4UHDB5	Definitive	Biomarker	[420]
TEKT4	OT1GMBOX	Definitive	Biomarker	[421]
TFE3	OTM99ZWH	Definitive	Genetic Variation	[422]
THAP1	OTIWUSON	Definitive	Biomarker	[416]
TLK1	OTICTXI8	Definitive	Altered Expression	[160]
TMEM139	OTZA6I9L	Definitive	Biomarker	[148]
TMPRSS13	OTMAOAP3	Definitive	Posttranslational Modification	[398]
TMPRSS4	OTCCGY2K	Definitive	Altered Expression	[423]
TNFAIP8L2	OTII0RM0	Definitive	Altered Expression	[424]
TPI1	OT14KP4B	Definitive	Biomarker	[425]
TRIM29	OT2DNESG	Definitive	Biomarker	[426]

References

• [1] Lenvatinib FDA Label
• [2] Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.Cancer Cytopathol. 2016 May;124(5):340-9. doi: 10.1002/cncy.21681. Epub 2016 Jan 7.
• [3] Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas.J Endocrinol Invest. 1999 Apr;22(4):273-8. doi: 10.1007/BF03343556.
• [4] Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma.J Mol Neurosci. 2016 Oct;60(2):171-8. doi: 10.1007/s12031-016-0823-7. Epub 2016 Aug 26.
• [5] A novel RET rearrangement (ACBD5/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation.Oncol Rep. 2014 Nov;32(5):1809-14. doi: 10.3892/or.2014.3449. Epub 2014 Aug 29.
• [6] ApolipoproteinL1 is expressed in papillary thyroid carcinomas.Pathol Res Pract. 2016 Jul;212(7):631-5. doi: 10.1016/j.prp.2016.04.004. Epub 2016 Apr 24.
• [7] No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma.Endocr J. 2006 Oct;53(5):615-20. doi: 10.1507/endocrj.k06-058. Epub 2006 Aug 8.
• [8] Sorting nexin 5 of a new diagnostic marker of papillary thyroid carcinoma regulates Caspase-2.Cancer Sci. 2012 Jul;103(7):1356-62. doi: 10.1111/j.1349-7006.2012.02296.x. Epub 2012 Jun 4.
• [9] Association of CD1a-positive dendritic cells with papillary thyroid carcinoma in thyroid fine-needle aspirations: a cytologic and immunocytochemical evaluation.Cancer Cytopathol. 2013 Apr;121(4):206-13. doi: 10.1002/cncy.21239. Epub 2012 Oct 5.
• [10] Downregulation of cyclin-dependent kinase 8 by microRNA-148a suppresses proliferation and invasiveness of papillary thyroid carcinomas.Am J Cancer Res. 2017 Oct 1;7(10):2081-2090. eCollection 2017.
• [11] Circadian clock characteristics are altered in human thyroid malignant nodules.J Clin Endocrinol Metab. 2013 Nov;98(11):4446-56. doi: 10.1210/jc.2013-2568. Epub 2013 Aug 26.
• [12] A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples.Mod Pathol. 2007 Oct;20(10):1095-102. doi: 10.1038/modpathol.3800943. Epub 2007 Jul 27.
• [13] Increased expression of mRNA specific for thymidine kinase, deoxycytidine kinase or thymidine phosphorylase in human papillary thyroid carcinoma.Cancer Lett. 2005 Jul 28;225(2):267-73. doi: 10.1016/j.canlet.2004.10.044. Epub 2004 Dec 9.
• [14] Values of ultrasound features and MMP-9 of papillary thyroid carcinoma in predicting cervical lymph node metastases.Sci Rep. 2017 Jul 27;7(1):6670. doi: 10.1038/s41598-017-07118-7.
• [15] Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.World J Surg. 2014 Jun;38(6):1296-305. doi: 10.1007/s00268-014-2485-3.
• [16] The cellular localization of autotaxin impacts on its biological functions in human thyroid carcinoma cells.Oncol Rep. 2008 Jun;19(6):1485-91.
• [17] EphB3 Stimulates Cell Migration and Metastasis in a Kinase-dependent Manner through Vav2-Rho GTPase Axis in Papillary Thyroid Cancer.J Biol Chem. 2017 Jan 20;292(3):1112-1121. doi: 10.1074/jbc.M116.750349. Epub 2016 Dec 16.
• [18] The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing.Nat Commun. 2017 Jun 5;8:15533. doi: 10.1038/ncomms15533.
• [19] Dual malignancy in a thyroid; papillary thyroid carcinoma and small lymphocytic lymphoma; a report of a case with a cyto-histologic correlation.Diagn Cytopathol. 2017 Sep;45(9):851-856. doi: 10.1002/dc.23748. Epub 2017 May 22.
• [20] Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid carcinoma from externally irradiated patient.Mutat Res. 2003 Jun 19;527(1-2):81-90. doi: 10.1016/s0027-5107(03)00056-3.
• [21] Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol.Thyroid. 2014 Feb;24(2):327-38. doi: 10.1089/thy.2012.0544. Epub 2014 Jan 9.
• [22] Expression of Gp78/Autocrine Motility Factor Receptor and Endocytosis of Autocrine Motility Factor in Human Thyroid Cancer Cells.Cureus. 2019 Jun 17;11(6):e4928. doi: 10.7759/cureus.4928.
• [23] Development of an ammonium sulfate DNA extraction method for obtaining amplifiable DNA in a small number of cells and its application to clinical specimens.Biomed Res Int. 2013;2013:546727. doi: 10.1155/2013/546727. Epub 2013 Apr 17.
• [24] Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells.Endocr Relat Cancer. 2011 Nov 14;18(6):687-97. doi: 10.1530/ERC-11-0212. Print 2011 Dec.
• [25] Preoperative RAS mutational analysis is of great value in predicting follicular variant of papillary thyroid carcinoma.Biomed Res Int. 2015;2015:697068. doi: 10.1155/2015/697068. Epub 2015 Jan 12.
• [26] Expression of the thyroid hormone receptor, the oncogenes c-myc and H-ras, and the 90 kD heat shock protein in normal, hyperplastic, and neoplastic human thyroid tissue.Thyroid. 1992 Winter;2(4):307-13. doi: 10.1089/thy.1992.2.307.
• [27] Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors.Oncol Rep. 2012 Nov;28(5):1838-44. doi: 10.3892/or.2012.1988. Epub 2012 Aug 23.
• [28] Associations between promoter polymorphism -106A/G of interleukin-11 receptor alpha and papillary thyroid cancer in Korean population.Surgery. 2012 Feb;151(2):323-9. doi: 10.1016/j.surg.2011.07.014. Epub 2011 Oct 6.
• [29] Microarray analysis of papillary thyroid cancers in Korean.Korean J Intern Med. 2010 Dec;25(4):399-407. doi: 10.3904/kjim.2010.25.4.399. Epub 2010 Nov 27.
• [30] KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer.J Mol Endocrinol. 2015 Apr;54(2):115-24. doi: 10.1530/JME-14-0270. Epub 2015 Jan 21.
• [31] Polyclonal B-cell expansion in the cerebrospinal fluid of patients with pseudotumor cerebri.J Clin Immunol. 2004 Nov;24(6):674-82. doi: 10.1007/s10875-004-6242-5.
• [32] Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma.J Clin Endocrinol Metab. 2005 Aug;90(8):4703-9. doi: 10.1210/jc.2004-2459. Epub 2005 May 17.
• [33] miR-125a-3p suppresses the growth and progression of papillary thyroid carcinoma cell by targeting MMP11.J Cell Biochem. 2020 Feb;121(2):984-995. doi: 10.1002/jcb.29333. Epub 2019 Sep 6.
• [34] Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma.Endocr Relat Cancer. 2009 Jun;16(2):491-503. doi: 10.1677/ERC-08-0336. Epub 2009 Mar 13.
• [35] P21-activated kinase 4 involves TSH induced papillary thyroid cancer cell proliferation.Oncotarget. 2017 Apr 11;8(15):24882-24891. doi: 10.18632/oncotarget.15079.
• [36] The human poly(ADP-ribose) glycohydrolase maps to chromosome 10q11.23-21.1 by fluorescence in situ hybridization.Hum Cell. 1998 Dec;11(4):243-6.
• [37] Nuclear localisation of endogenous SUMO-1-modified PDGF-C in human thyroid tissue and cell lines.Exp Cell Res. 2006 Apr 1;312(6):782-95. doi: 10.1016/j.yexcr.2005.11.035. Epub 2006 Jan 26.
• [38] Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype.J Transl Med. 2016 Jun 8;14(1):168. doi: 10.1186/s12967-016-0915-8.
• [39] Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.BMC Cancer. 2008 May 23;8:144. doi: 10.1186/1471-2407-8-144.
• [40] MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.Int J Cancer. 2014 Jan 15;134(2):257-67. doi: 10.1002/ijc.28141. Epub 2013 Sep 18.
• [41] Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma.PLoS One. 2016 Jun 1;11(6):e0156658. doi: 10.1371/journal.pone.0156658. eCollection 2016.
• [42] Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth.Mod Pathol. 2005 Feb;18(2):221-7. doi: 10.1038/modpathol.3800285.
• [43] Role of PTPRJ genotype in papillary thyroid carcinoma risk.Endocr Relat Cancer. 2010 Oct 29;17(4):1001-6. doi: 10.1677/ERC-10-0143. Print 2010 Dec.
• [44] FN1, GALE, MET, and QPCT overexpression in papillary thyroid carcinoma: molecular analysis using frozen tissue and routine fine-needle aspiration biopsy samples.Diagn Cytopathol. 2011 Aug;39(8):556-61. doi: 10.1002/dc.21423. Epub 2010 Jul 6.
• [45] Expression of the cAMP binding protein EPAC1 in thyroid tumors and growth regulation of thyroid cells and thyroid carcinoma cells by EPAC proteins.Horm Metab Res. 2015 Mar;47(3):200-8. doi: 10.1055/s-0034-1390484. Epub 2014 Nov 5.
• [46] Higher expression level of tyrosine kinase-like orphan receptor 2 and Wnt member 5a in papillary thyroid carcinoma is associated with poor prognosis.Oncol Lett. 2017 Nov;14(5):5966-5972. doi: 10.3892/ol.2017.6989. Epub 2017 Sep 18.
• [47] LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.Oncotarget. 2015 Oct 27;6(33):34549-60. doi: 10.18632/oncotarget.5330.
• [48] Retinoid X receptor up-regulation is correlated with dedifferentiation of tumor cells and lymph node metastasis in papillary thyroid carcinoma.Pathol Int. 2011 Mar;61(3):109-15. doi: 10.1111/j.1440-1827.2010.02623.x. Epub 2010 Dec 8.
• [49] Silencing of the maspin gene by promoter hypermethylation in thyroid cancer.Int J Mol Med. 2003 Oct;12(4):479-84.
• [50] BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.Eur J Endocrinol. 2015 Oct;173(4):525-40. doi: 10.1530/EJE-15-0254.
• [51] LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.Oncotarget. 2017 Apr 4;8(14):22954-22967. doi: 10.18632/oncotarget.14578.
• [52] Long noncoding RNA SAMMSON promotes papillary thyroid carcinoma progression through p300/Sp1 axis and serves as a novel diagnostic and prognostic biomarker.IUBMB Life. 2020 Feb;72(2):237-246. doi: 10.1002/iub.2158. Epub 2019 Sep 3.
• [53] iTRAQ-coupled 2D LC/MS-MS analysis of CXCR7-transfected papillary thyroid carcinoma cells: A new insight into CXCR7 regulation of papillary thyroid carcinoma progression and identification of potential biomarkers.Oncol Lett. 2017 Sep;14(3):3734-3740. doi: 10.3892/ol.2017.6574. Epub 2017 Jul 15.
• [54] Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases.Cancer. 2008 Sep 1;113(5):936-44. doi: 10.1002/cncr.23683.
• [55] A missense polymorphism (rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with tumor size of papillary thyroid carcinoma in the Korean population.Endocrine. 2013 Feb;43(1):161-9. doi: 10.1007/s12020-012-9783-z. Epub 2012 Nov 3.
• [56] Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas.Oncogene. 2002 Jul 18;21(31):4830-7. doi: 10.1038/sj.onc.1205612.
• [57] TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.Oncotarget. 2016 Oct 25;7(43):70575-70588. doi: 10.18632/oncotarget.12129.
• [58] Upregulation of glucosylceramide synthase protein in papillary thyroid carcinoma.Chin Med J (Engl). 2013;126(24):4660-4.
• [59] HLA-G 3' untranslated region polymorphic sites associated with increased HLA-G production are more frequent in patients exhibiting differentiated thyroid tumours.Clin Endocrinol (Oxf). 2017 Apr;86(4):597-605. doi: 10.1111/cen.13289. Epub 2017 Jan 10.
• [60] Paratubal Cyst Size Correlates With Obesity and Dysregulation of the Wnt Signaling Pathway.J Pediatr Adolesc Gynecol. 2017 Oct;30(5):571-577. doi: 10.1016/j.jpag.2017.04.002. Epub 2017 Apr 27.
• [61] Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study.Int J Biol Markers. 2018 Nov;33(4):455-462. doi: 10.1177/1724600818787752. Epub 2018 Jul 30.
• [62] Genetic expression profile-based screening of genes and pathways associated with papillary thyroid carcinoma.Oncol Lett. 2018 Nov;16(5):5723-5732. doi: 10.3892/ol.2018.9342. Epub 2018 Aug 21.
• [63] The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results.Immunol Res. 2018 Dec;66(6):710-722. doi: 10.1007/s12026-018-9056-x.
• [64] Alteration in the serum concentrations of FGF19, FGFR4 and Klotho in patients with thyroid cancer.Cytokine. 2018 May;105:32-36. doi: 10.1016/j.cyto.2018.02.013. Epub 2018 Feb 10.
• [65] Applicability of sentinel lymph node biopsy in papillary thyroid cancer.Q J Nucl Med Mol Imaging. 2020 Dec;64(4):400-405. doi: 10.23736/S1824-4785.18.03097-2. Epub 2018 Jul 9.
• [66] Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation.J Neurol. 2018 Sep;265(9):1985-1988. doi: 10.1007/s00415-018-8956-y. Epub 2018 Jun 25.
• [67] The clinical significance of PINX1 expression in papillary thyroid carcinoma.Hum Pathol. 2018 Nov;81:176-183. doi: 10.1016/j.humpath.2018.07.004. Epub 2018 Jul 17.
• [68] Iodine regulates G2/M progression induced by CCL21/CCR7 interaction in primary cultures of papillary thyroid cancer cells with RET/PTC expression.Mol Med Rep. 2016 Oct;14(4):3941-6. doi: 10.3892/mmr.2016.5686. Epub 2016 Aug 29.
• [69] Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.Mol Cancer. 2013 Oct 20;12(1):124. doi: 10.1186/1476-4598-12-124.
• [70] Identification of epistatic interactions through genome-wide association studies in sporadic medullary and juvenile papillary thyroid carcinomas.BMC Med Genomics. 2015 Dec 21;8:83. doi: 10.1186/s12920-015-0160-7.
• [71] Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.Genet Mol Res. 2015 Dec 29;14(4):18886-94. doi: 10.4238/2015.December.28.38.
• [72] Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression.J Cell Physiol. 2018 Oct;233(10):6638-6648. doi: 10.1002/jcp.26425. Epub 2018 May 10.
• [73] SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.Surgery. 2014 Dec;156(6):1542-8; discussion 1548-9. doi: 10.1016/j.surg.2014.08.095. Epub 2014 Nov 11.
• [74] p63 inhibits CD44(+)/CD24(-) cell proliferation and chemoresistance in papillary thyroid carcinoma cells.Exp Ther Med. 2017 Nov;14(5):4693-4696. doi: 10.3892/etm.2017.5137. Epub 2017 Sep 19.
• [75] SIRT6/HIF-1 axis promotes papillary thyroid cancer progression by inducing epithelial-mesenchymal transition.Cancer Cell Int. 2019 Jan 16;19:17. doi: 10.1186/s12935-019-0730-4. eCollection 2019.
• [76] Long noncoding RNA LINC00460 promotes carcinogenesis via sponging miR-613 in papillary thyroid carcinoma.J Cell Physiol. 2019 Jul;234(7):11431-11439. doi: 10.1002/jcp.27799. Epub 2018 Nov 27.
• [77] The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.Eur Arch Otorhinolaryngol. 2018 Aug;275(8):2127-2134. doi: 10.1007/s00405-018-5045-x. Epub 2018 Jun 27.
• [78] Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells.J Pathol. 2007 Aug;212(4):411-9. doi: 10.1002/path.2183.
• [79] MicroRNA-26a-5p inhibits proliferation, invasion and metastasis by repressing the expression of Wnt5a in papillary thyroid carcinoma.Onco Targets Ther. 2019 Aug 16;12:6605-6616. doi: 10.2147/OTT.S205994. eCollection 2019.
• [80] AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma.Pediatr Blood Cancer. 2019 Jul;66(7):e27707. doi: 10.1002/pbc.27707. Epub 2019 Mar 29.
• [81] A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.Cell Death Dis. 2019 Jun 3;10(6):433. doi: 10.1038/s41419-019-1637-7.
• [82] Characterization of thyroid cancer driven by known and novel ALK fusions.Endocr Relat Cancer. 2019 Nov;26(11):803-814. doi: 10.1530/ERC-19-0325.
• [83] Identification of potential pathogenic candidates or diagnostic biomarkers in papillary thyroid carcinoma using expression and methylation profiles.Oncol Lett. 2019 Dec;18(6):6670-6678. doi: 10.3892/ol.2019.11059. Epub 2019 Nov 5.
• [84] MiR-630 inhibits papillary thyroid carcinoma cell growth, metastasis, and epithelial-mesenchymal transition by suppressing JAK2/STAT3 signaling pathway.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2453-2460. doi: 10.26355/eurrev_201903_17392.
• [85] Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy.Oncogene. 2017 Feb 2;36(5):667-677. doi: 10.1038/onc.2016.237. Epub 2016 Jul 4.
• [86] CHK2 Promotes Anoikis and is Associated with the Progression of Papillary Thyroid Cancer.Cell Physiol Biochem. 2018;45(4):1590-1602. doi: 10.1159/000487724. Epub 2018 Feb 21.
• [87] Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery.Oncotarget. 2018 Jan 4;9(15):12079-12100. doi: 10.18632/oncotarget.23951. eCollection 2018 Feb 23.
• [88] MicroRNA-101 Targets CXCL12-Mediated Akt and Snail Signaling Pathways to Inhibit Cellular Proliferation and Invasion in Papillary Thyroid Carcinoma.Oncol Res. 2019 Jun 21;27(6):691-701. doi: 10.3727/096504018X15426763753594. Epub 2019 Mar 4.
• [89] CXXC5 expression in prostate cancer: implications for cancer progression.Int J Exp Pathol. 2017 Aug;98(4):234-243. doi: 10.1111/iep.12241.
• [90] Cyp24a1 Attenuation Limits Progression of Braf(V600E) -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF(V600E) Inhibitor PLX4720.Cancer Res. 2017 Apr 15;77(8):2161-2172. doi: 10.1158/0008-5472.CAN-16-2066. Epub 2017 Feb 27.
• [91] DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway.Oncol Lett. 2017 Dec;14(6):8114-8121. doi: 10.3892/ol.2017.7250. Epub 2017 Oct 23.
• [92] GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.Oncogene. 2019 Feb;38(7):965-979. doi: 10.1038/s41388-018-0483-x. Epub 2018 Sep 4.
• [93] Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.Cancer Biomark. 2019;24(1):7-17. doi: 10.3233/CBM-170908.
• [94] Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma.Thorac Cancer. 2020 Feb;11(2):336-345. doi: 10.1111/1759-7714.13270. Epub 2019 Dec 10.
• [95] Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells.Br J Cancer. 2008 Sep 2;99(5):781-8. doi: 10.1038/sj.bjc.6604544.
• [96] Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia.J Oncol Pharm Pract. 2019 Dec;25(8):2010-2015. doi: 10.1177/1078155218816768. Epub 2018 Dec 4.
• [97] Overexpression of Forkhead box Q1 correlates with poor prognosis in papillary thyroid carcinoma.Clin Endocrinol (Oxf). 2019 Feb;90(2):334-342. doi: 10.1111/cen.13896. Epub 2018 Dec 17.
• [98] GABRB2 plays an important role in the lymph node metastasis of papillary thyroid cancer.Biochem Biophys Res Commun. 2017 Oct 21;492(3):323-330. doi: 10.1016/j.bbrc.2017.08.114. Epub 2017 Aug 30.
• [99] Tumor promoting effects of glucagon receptor: a promising biomarker of papillary thyroid carcinoma via regulating EMT and P38/ERK pathways.Hum Cell. 2020 Jan;33(1):175-184. doi: 10.1007/s13577-019-00284-y. Epub 2019 Nov 28.
• [100] GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.Oncotarget. 2019 Jun 25;10(41):4107-4124. doi: 10.18632/oncotarget.26993. eCollection 2019 Jun 25.
• [101] The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.PLoS One. 2011;6(6):e20665. doi: 10.1371/journal.pone.0020665. Epub 2011 Jun 17.
• [102] Oncofoetal fibronectin--a tumour-specific marker in detecting minimal residual disease in differentiated thyroid carcinoma.Br J Cancer. 2005 Sep 5;93(5):565-70. doi: 10.1038/sj.bjc.6602741.
• [103] Knockdown of lncRNA UCA1 inhibits proliferation and invasion of papillary thyroid carcinoma through regulating miR-204/IGFBP5 axis.Onco Targets Ther. 2018 Oct 18;11:7197-7204. doi: 10.2147/OTT.S175467. eCollection 2018.
• [104] IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma.J Clin Endocrinol Metab. 2019 Nov 1;104(11):5573-5584. doi: 10.1210/jc.2019-00040.
• [105] Association of IRAK1 Gene Polymorphism rs3027898 With Papillary Cancer Restricted to the Thyroid Gland: A Pilot Study.In Vivo. 2019 Nov-Dec;33(6):2281-2285. doi: 10.21873/invivo.11734.
• [106] CircRNA circ-ITCH suppresses papillary thyroid cancer progression through miR-22-3p/CBL/-catenin pathway.Biochem Biophys Res Commun. 2018 Sep 26;504(1):283-288. doi: 10.1016/j.bbrc.2018.08.175. Epub 2018 Sep 4.
• [107] The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.Surg Oncol. 2018 Dec;27(4):702-708. doi: 10.1016/j.suronc.2018.09.007. Epub 2018 Sep 22.
• [108] Knockdown of KDM1A suppresses tumour migration and invasion by epigenetically regulating the TIMP1/MMP9 pathway in papillary thyroid cancer.J Cell Mol Med. 2019 Aug;23(8):4933-4944. doi: 10.1111/jcmm.14311. Epub 2019 Jun 18.
• [109] Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer.Cancers (Basel). 2019 Aug 12;11(8):1154. doi: 10.3390/cancers11081154.
• [110] Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease.Endocrine. 2019 Jun;64(3):622-631. doi: 10.1007/s12020-019-01878-0. Epub 2019 Mar 2.
• [111] Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze.Pathol Oncol Res. 2019 Jan;25(1):401-408. doi: 10.1007/s12253-017-0337-9. Epub 2017 Nov 17.
• [112] LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals.Sci Rep. 2018 Feb 9;8(1):2718. doi: 10.1038/s41598-018-21216-0.
• [113] Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression.Oncotarget. 2017 Nov 25;8(70):114980-114994. doi: 10.18632/oncotarget.22692. eCollection 2017 Dec 29.
• [114] Expression of proteins related to autotaxin-lysophosphatidate signaling in thyroid tumors.J Transl Med. 2019 Aug 28;17(1):288. doi: 10.1186/s12967-019-2028-7.
• [115] Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations.Hum Mol Genet. 2016 May 1;25(9):1875-84. doi: 10.1093/hmg/ddw056. Epub 2016 Mar 2.
• [116] Increased Expression of GARP in Papillary Thyroid Carcinoma.Endocr Pathol. 2019 Mar;30(1):1-7. doi: 10.1007/s12022-018-9557-0.
• [117] KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.J Natl Compr Canc Netw. 2019 May 1;17(5):409-413. doi: 10.6004/jnccn.2019.7292.
• [118] Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma.Biomed Pharmacother. 2019 Jun;114:108605. doi: 10.1016/j.biopha.2019.108605. Epub 2019 Mar 21.
• [119] Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer.Medicine (Baltimore). 2018 Sep;97(36):e12242. doi: 10.1097/MD.0000000000012242.
• [120] AEG-1 associates with metastasis in papillary thyroid cancer through upregulation of MMP2/9.Int J Oncol. 2017 Sep;51(3):812-822. doi: 10.3892/ijo.2017.4074. Epub 2017 Jul 17.
• [121] Characterization and significance of MUC1 and c-myc expression in elderly patients with papillary thyroid carcinoma.Genet Mol Res. 2015 Nov 30;14(4):15325-30. doi: 10.4238/2015.November.30.9.
• [122] The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly.Exp Clin Endocrinol Diabetes. 2019 Jul;127(7):437-444. doi: 10.1055/a-0629-9223. Epub 2018 Jun 11.
• [123] Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma.Genes Chromosomes Cancer. 2019 Aug;58(8):558-566. doi: 10.1002/gcc.22737. Epub 2019 Feb 18.
• [124] Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid.Br J Cancer. 2005 May 23;92(10):1892-8. doi: 10.1038/sj.bjc.6602547.
• [125] Erratum: NECTIN4 Promotes Papillary Thyroid Cancer Cell Proliferation, Migration, and Invasion and Triggers EMT by Activating AKT [Corrigendum].Cancer Manag Res. 2019 Nov 28;11:10041. doi: 10.2147/CMAR.S239515. eCollection 2019.
• [126] Somatic genetic alterations in a large cohort of pediatric thyroid nodules.Endocr Connect. 2019 Jun;8(6):796-805. doi: 10.1530/EC-19-0069.
• [127] The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.J Clin Endocrinol Metab. 2018 Apr 1;103(4):1369-1379. doi: 10.1210/jc.2017-01798.
• [128] Sporadic pediatric papillary thyroid carcinoma harboring the ETV6/NTRK3 fusion oncogene in a 7-year-old Japanese girl: a case report and review of literature.J Pediatr Endocrinol Metab. 2018 Mar 28;31(4):461-467. doi: 10.1515/jpem-2017-0292.
• [129] Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.BMC Cancer. 2009 Oct 18;9:369. doi: 10.1186/1471-2407-9-369.
• [130] The role of oncostatin M receptor gene polymorphisms in bladder cancer.World J Surg Oncol. 2019 Feb 12;17(1):30. doi: 10.1186/s12957-018-1555-7.
• [131] Autocrine activation of platelet-derived growth factor receptor in metastatic papillary thyroid cancer.Hum Pathol. 2018 May;75:146-153. doi: 10.1016/j.humpath.2018.01.025. Epub 2018 Feb 2.
• [132] miR-718 is involved in malignancy of papillary thyroid cancer through repression of PDPK1.Pathol Res Pract. 2018 Nov;214(11):1787-1793. doi: 10.1016/j.prp.2018.08.022. Epub 2018 Aug 24.
• [133] Low frequency of PAX8-PPAR rearrangement in follicular thyroid carcinomas in Japanese patients.Pathol Int. 2015 May;65(5):250-3. doi: 10.1111/pin.12270. Epub 2015 Feb 23.
• [134] LncRNA CRNDE promotes cell proliferation, invasion and migration by competitively binding miR-384 in papillary thyroid cancer.Oncotarget. 2017 Nov 30;8(66):110552-110565. doi: 10.18632/oncotarget.22819. eCollection 2017 Dec 15.
• [135] Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma. Thyroid. 2011 Nov;21(11):1217-25.
• [136] Causal associations of autoimmune thyroiditis and papillary thyroid carcinoma: mRNA expression of selected nuclear receptors and other molecular targets.Oncol Lett. 2019 Oct;18(4):4270-4277. doi: 10.3892/ol.2019.10770. Epub 2019 Aug 22.
• [137] lncRNA RPL34-AS1 inhibits cell proliferation and invasion while promoting apoptosis by competitively binding miR-3663-3p/RGS4 in papillary thyroid cancer.J Cell Physiol. 2020 Apr;235(4):3669-3678. doi: 10.1002/jcp.29256. Epub 2019 Oct 6.
• [138] MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8940-8949. doi: 10.26355/eurrev_201910_19292.
• [139] Transcription Factor HOXA9 is Linked to the Calcification and Invasion of Papillary Thyroid Carcinoma.Sci Rep. 2019 May 1;9(1):6773. doi: 10.1038/s41598-019-43207-5.
• [140] Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.Cell Physiol Biochem. 2018;50(5):1659-1672. doi: 10.1159/000494786. Epub 2018 Nov 1.
• [141] A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours.BMC Cancer. 2015 Mar 29;15:199. doi: 10.1186/s12885-015-1217-x.
• [142] Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma.Oncol Rep. 2019 Feb;41(2):1253-1263. doi: 10.3892/or.2018.6895. Epub 2018 Nov 28.
• [143] Rapid Growth and Early Metastasis of Papillary Thyroid Carcinoma in an Adolescent Girl with Graves' Disease.Horm Res Paediatr. 2019;91(3):210-215. doi: 10.1159/000491102. Epub 2018 Aug 9.
• [144] MiR-128 suppresses the growth of thyroid carcinoma by negatively regulating SPHK1.Biomed Pharmacother. 2019 Jan;109:1960-1966. doi: 10.1016/j.biopha.2018.08.052. Epub 2018 Nov 26.
• [145] Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF1 Axis.Clin Cancer Res. 2018 Dec 1;24(23):6078-6097. doi: 10.1158/1078-0432.CCR-18-0693. Epub 2018 Aug 3.
• [146] Reduced expression of THR in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.J Endocrinol Invest. 2015 Dec;38(12):1283-9. doi: 10.1007/s40618-015-0309-4. Epub 2015 May 24.
• [147] Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.J Clin Endocrinol Metab. 2019 Aug 1;104(8):3557-3575. doi: 10.1210/jc.2018-01167.
• [148] A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.Clin Exp Metastasis. 2020 Apr;37(2):257-267. doi: 10.1007/s10585-019-10011-4. Epub 2019 Dec 2.
• [149] Hyperinsulinemia and thyroid peroxidase antibody in Chinese patients with papillary thyroid cancer.Endocr J. 2019 Aug 29;66(8):731-737. doi: 10.1507/endocrj.EJ18-0358. Epub 2019 May 22.
• [150] RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.Eur J Endocrinol. 2006 Nov;155(5):645-53. doi: 10.1530/eje.1.02289.
• [151] DNA methylation-mediated silencing of miR-204 is a potential prognostic marker for papillary thyroid carcinoma.Cancer Manag Res. 2019 Feb 8;11:1249-1262. doi: 10.2147/CMAR.S184566. eCollection 2019.
• [152] Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma.Head Neck. 2019 Aug;41(8):2602-2609. doi: 10.1002/hed.25729. Epub 2019 Mar 7.
• [153] Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.Oncotarget. 2017 Feb 7;8(6):9597-9607. doi: 10.18632/oncotarget.14162.
• [154] NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer.Cell Death Dis. 2018 Mar 7;9(3):380. doi: 10.1038/s41419-018-0418-z.
• [155] Cyclin-dependent kinase 7 is a potential therapeutic target in papillary thyroid carcinoma.J Biol Regul Homeost Agents. 2018 Nov-Dec;32(6):1361-1368.
• [156] CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.Cell Death Dis. 2018 Mar 7;9(3):371. doi: 10.1038/s41419-018-0352-0.
• [157] Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition.J Cell Mol Med. 2019 Dec;23(12):7974-7984. doi: 10.1111/jcmm.14460. Epub 2019 Sep 30.
• [158] Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer invitro.Oncol Rep. 2018 May;39(5):2185-2192. doi: 10.3892/or.2018.6295. Epub 2018 Mar 5.
• [159] Long non-coding RNA MIAT promotes papillary thyroid cancer progression through upregulating LASP1.Cancer Cell Int. 2019 Jul 25;19:194. doi: 10.1186/s12935-019-0913-z. eCollection 2019.
• [160] Ang1/Tie2 induces cell proliferation and migration in human papillary thyroid carcinoma via the PI3K/AKT pathway.Oncol Lett. 2018 Jan;15(1):1313-1318. doi: 10.3892/ol.2017.7367. Epub 2017 Nov 8.
• [161] Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance.Hum Pathol. 2018 Jan;71:74-83. doi: 10.1016/j.humpath.2017.10.015. Epub 2017 Oct 24.
• [162] Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis.Cell Death Dis. 2019 Aug 14;10(8):620. doi: 10.1038/s41419-019-1850-4.
• [163] Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma.World J Surg Oncol. 2018 Dec 17;16(1):235. doi: 10.1186/s12957-018-1535-y.
• [164] Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.Med Sci Monit. 2018 Oct 15;24:7357-7365. doi: 10.12659/MSM.910168.
• [165] USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.Cell Physiol Biochem. 2018;45(5):2044-2053. doi: 10.1159/000488041. Epub 2018 Mar 7.
• [166] Expression of WD Repeat Domain 5 (WDR5) is Associated with Progression and Reduced Prognosis in Papillary Thyroid Carcinoma.Med Sci Monit. 2019 May 20;25:3762-3770. doi: 10.12659/MSM.915847.
• [167] Monocarboxylate transporter 8 deficiency: altered thyroid morphology and persistent high triiodothyronine/thyroxine ratio after thyroidectomy.Eur J Endocrinol. 2011 Oct;165(4):555-61. doi: 10.1530/EJE-11-0369. Epub 2011 Aug 3.
• [168] Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer. Biomed Pharmacother. 2013 Oct;67(8):723-30.
• [169] Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.Clin Cancer Res. 2008 Aug 1;14(15):4735-42. doi: 10.1158/1078-0432.CCR-07-4372.
• [170] Metallothionein Isoform Expression in Benign and Malignant Thyroid Lesions.Anticancer Res. 2017 Sep;37(9):5179-5185. doi: 10.21873/anticanres.11940.
• [171] Vitamin D-neutralizing CYP24A1 expression, oncogenic mutation states and histological findings of human papillary thyroid cancer.J Endocrinol Invest. 2015 Mar;38(3):313-21. doi: 10.1007/s40618-014-0165-7. Epub 2014 Sep 9.
• [172] Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma.Thyroid. 2012 Jul;22(7):709-16. doi: 10.1089/thy.2011.0330. Epub 2012 Jun 12.
• [173] Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells.Mol Endocrinol. 2005 Feb;19(2):527-39. doi: 10.1210/me.2004-0215. Epub 2004 Oct 14.
• [174] Up-Regulated AKR1C2 is correlated with favorable prognosis in thyroid carcinoma.J Cancer. 2019 Jun 9;10(15):3543-3552. doi: 10.7150/jca.28364. eCollection 2019.
• [175] Validation of Reference Genes for Normalization of Relative qRT-PCR Studies in Papillary Thyroid Carcinoma.Sci Rep. 2019 Oct 23;9(1):15241. doi: 10.1038/s41598-019-49247-1.
• [176] Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer.Surgery. 2014 Dec;156(6):1342-50; discussion 1350. doi: 10.1016/j.surg.2014.08.007. Epub 2014 Nov 11.
• [177] XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.Oncogene. 2009 Feb 19;28(7):937-49. doi: 10.1038/onc.2008.447. Epub 2008 Dec 8.
• [178] Afamin promotes glucose metabolism in papillary thyroid carcinoma.Mol Cell Endocrinol. 2016 Oct 15;434:108-15. doi: 10.1016/j.mce.2016.06.013. Epub 2016 Jun 18.
• [179] Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.Pathol Oncol Res. 2012 Apr;18(2):449-58. doi: 10.1007/s12253-011-9467-7. Epub 2011 Dec 11.
• [180] Expression of MAGE A1-6 and the clinical characteristics of papillary thyroid carcinoma.Anticancer Res. 2013 Apr;33(4):1731-5.
• [181] Anoctamin5 regulates cell migration and invasion in thyroid cancer.Int J Oncol. 2017 Oct;51(4):1311-1319. doi: 10.3892/ijo.2017.4113. Epub 2017 Sep 1.
• [182] A unique case of two somatic APC mutations in an early onset cribriform-morular variant of papillary thyroid carcinoma and overview of the literature.Fam Cancer. 2020 Jan;19(1):15-21. doi: 10.1007/s10689-019-00146-4.
• [183] New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma.Oncotarget. 2015 May 10;6(13):11242-51. doi: 10.18632/oncotarget.3593.
• [184] Germline bone morphogenesis protein receptor 1A mutation causes colorectal tumorigenesis in hereditary mixed polyposis syndrome.Am J Gastroenterol. 2009 Dec;104(12):3027-33. doi: 10.1038/ajg.2009.542. Epub 2009 Sep 22.
• [185] Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.Anticancer Res. 2008 Jan-Feb;28(1A):139-44.
• [186] Cyclin A1 is a transcriptional target of PITX2 and overexpressed in papillary thyroid carcinoma.Mol Cell Biochem. 2013 Dec;384(1-2):221-7. doi: 10.1007/s11010-013-1801-9. Epub 2013 Sep 4.
• [187] Cell division cycle 45 promotes papillary thyroid cancer progression via regulating cell cycle.Tumour Biol. 2017 May;39(5):1010428317705342. doi: 10.1177/1010428317705342.
• [188] miR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma.Biochem Biophys Res Commun. 2014 Jul 18;450(1):857-62. doi: 10.1016/j.bbrc.2014.06.073. Epub 2014 Jun 24.
• [189] miR-26a and its target CKS2 modulate cell growth and tumorigenesis of papillary thyroid carcinoma.PLoS One. 2013 Jul 5;8(7):e67591. doi: 10.1371/journal.pone.0067591. Print 2013.
• [190] Gene expression in poorly differentiated papillary thyroid carcinomas.Thyroid. 2006 Feb;16(2):161-75. doi: 10.1089/thy.2006.16.161.
• [191] Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma.Sci Rep. 2016 May 17;6:26037. doi: 10.1038/srep26037.
• [192] Cpt1c regulated by AMPK promotes papillary thyroid carcinomas cells survival under metabolic stress conditions.J Cancer. 2017 Oct 12;8(18):3675-3681. doi: 10.7150/jca.21148. eCollection 2017.
• [193] The clinical implications of Crk-like adaptor protein expression in papillary thyroid microcarcinoma.Tumour Biol. 2014 Dec;35(12):12435-40. doi: 10.1007/s13277-014-2561-1. Epub 2014 Sep 4.
• [194] Aberrant expression of COT is related to recurrence of papillary thyroid cancer.Medicine (Baltimore). 2015 Feb;94(6):e548. doi: 10.1097/MD.0000000000000548.
• [195] Identification of differentially expressed genes in papillary thyroid cancers.Yonsei Med J. 2009 Feb 28;50(1):60-7. doi: 10.3349/ymj.2009.50.1.60. Epub 2009 Feb 24.
• [196] Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics.Front Endocrinol (Lausanne). 2017 Oct 20;8:277. doi: 10.3389/fendo.2017.00277. eCollection 2017.
• [197] Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.Endocr Relat Cancer. 2009 Jun;16(2):467-81. doi: 10.1677/ERC-08-0081. Epub 2009 Feb 10.
• [198] Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers.J Hum Genet. 2004;49(6):312-318. doi: 10.1007/s10038-004-0146-3. Epub 2004 Apr 29.
• [199] The tumor-promoting function of ECRG4 in papillary thyroid carcinoma and its related mechanism.Tumour Biol. 2015 Feb;36(2):1081-9. doi: 10.1007/s13277-014-2731-1. Epub 2014 Oct 19.
• [200] RNA sequencing identifies crucial genes in papillary thyroid carcinoma (PTC) progression.Exp Mol Pathol. 2016 Feb;100(1):151-9. doi: 10.1016/j.yexmp.2015.12.011. Epub 2015 Dec 18.
• [201] Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.PLoS One. 2017 Mar 30;12(3):e0174737. doi: 10.1371/journal.pone.0174737. eCollection 2017.
• [202] Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.Oncotarget. 2016 Sep 6;7(36):57978-57990. doi: 10.18632/oncotarget.11154.
• [203] Absence of allelic imbalance involving EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma.J Endocrinol Invest. 2008 Jul;31(7):618-23. doi: 10.1007/BF03345613.
• [204] Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.Mol Cell Biol. 2001 Jul;21(13):4177-87. doi: 10.1128/MCB.21.13.4177-4187.2001.
• [205] Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.Oncotarget. 2017 Apr 18;8(16):27075-27092. doi: 10.18632/oncotarget.15635.
• [206] Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.Oncotarget. 2017 Apr 11;8(15):24457-24468. doi: 10.18632/oncotarget.14904.
• [207] Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.J Pathol. 2008 May;215(1):87-96. doi: 10.1002/path.2331.
• [208] MAGE-1, GAGE-1/-2 gene expression in FNAB of classic variant of papillary thyroid carcinoma and papillary hyperplasia in nodular goiter.Int J Mol Med. 1999 Oct;4(4):445-8. doi: 10.3892/ijmm.4.4.445.
• [209] Long noncoding RNA small nucleolar RNA host gene 12 promotes papillary thyroid carcinoma cell growth and invasion by targeting miR-16-5p.Histol Histopathol. 2020 Feb;35(2):217-224. doi: 10.14670/HH-18-155. Epub 2019 Jul 29.
• [210] HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma.Endocr Relat Cancer. 2007 Jun;14(2):445-52. doi: 10.1677/ERC-07-0039.
• [211] Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation.Anticancer Res. 2013 Oct;33(10):4357-64.
• [212] Common genetic variants related to genomic integrity and risk of papillary thyroid cancer.Carcinogenesis. 2011 Aug;32(8):1231-7. doi: 10.1093/carcin/bgr100. Epub 2011 Jun 3.
• [213] Association between interleukin 17/interleukin 17 receptor gene polymorphisms and papillary thyroid cancer in Korean population.Cytokine. 2015 Feb;71(2):283-8. doi: 10.1016/j.cyto.2014.11.011. Epub 2014 Dec 5.
• [214] Interleukin 22 polymorphisms and papillary thyroid cancer.J Endocrinol Invest. 2013 Sep;36(8):584-7. doi: 10.3275/8879. Epub 2013 Feb 27.
• [215] IQGAP1 plays an important role in the invasiveness of thyroid cancer.Clin Cancer Res. 2010 Dec 15;16(24):6009-18. doi: 10.1158/1078-0432.CCR-10-1627. Epub 2010 Oct 19.
• [216] Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases.Endocr Relat Cancer. 2015 Apr;22(2):205-16. doi: 10.1530/ERC-14-0351. Epub 2015 Feb 17.
• [217] Suppressed Krppellike factor 17 expression induces tumor proliferation, metastasis and a poor prognosis in papillary thyroid carcinoma.Mol Med Rep. 2014 Oct;10(4):2087-92. doi: 10.3892/mmr.2014.2429. Epub 2014 Jul 29.
• [218] The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.J Exp Clin Cancer Res. 2018 Sep 21;37(1):234. doi: 10.1186/s13046-018-0907-z.
• [219] Nuclear shape in papillary thyroid carcinoma: a role for lamin B receptor?.Rom J Morphol Embryol. 2010;51(4):615-20.
• [220] LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-B activation in papillary thyroid carcinoma.J Exp Clin Cancer Res. 2015 Dec 4;34:146. doi: 10.1186/s13046-015-0265-z.
• [221] Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma.Clin Endocrinol (Oxf). 2014 Jul;81(1):109-16. doi: 10.1111/cen.12396. Epub 2014 Jan 21.
• [222] Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.Thyroid. 2016 Sep;26(9):1276-84. doi: 10.1089/thy.2015.0665. Epub 2016 Jul 22.
• [223] MCM3 protein expression in follicular and classical variants of papillary thyroid carcinoma.Pathol Oncol Res. 2014 Jan;20(1):87-91. doi: 10.1007/s12253-013-9662-9. Epub 2013 Jul 3.
• [224] RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.J Clin Endocrinol Metab. 2014 Feb;99(2):E338-47. doi: 10.1210/jc.2013-2792. Epub 2013 Dec 2.
• [225] Identification of Genes Associated with Papillary Thyroid Carcinoma (PTC) for Diagnosis by Integrated Analysis.Horm Metab Res. 2016 Apr;48(4):226-31. doi: 10.1055/s-0035-1569289. Epub 2016 Jan 12.
• [226] PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway.Oncol Rep. 2015 Sep;34(3):1424-30. doi: 10.3892/or.2015.4096. Epub 2015 Jun 30.
• [227] A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma.Medicine (Baltimore). 2015 Jan;94(2):e380. doi: 10.1097/MD.0000000000000380.
• [228] Expression of N-acetyl transferase human and human Arrest defective 1 proteins in thyroid neoplasms.Thyroid. 2005 Oct;15(10):1131-6. doi: 10.1089/thy.2005.15.1131.
• [229] NATH, a novel gene overexpressed in papillary thyroid carcinomas.Oncogene. 2002 Aug 1;21(33):5056-68. doi: 10.1038/sj.onc.1205687.
• [230] A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma.Onco Targets Ther. 2018 Jan 11;11:307-311. doi: 10.2147/OTT.S154158. eCollection 2018.
• [231] Overexpression of NOTCH-regulated Ankyrin Repeat Protein is associated with papillary thyroid carcinoma progression.PLoS One. 2017 Feb 16;12(2):e0167782. doi: 10.1371/journal.pone.0167782. eCollection 2017.
• [232] Computed Tomography-Detected Central Lymph Node Metastasis in Ultrasonography Node-Negative Papillary Thyroid Carcinoma: Is It Really Significant?.Ann Surg Oncol. 2017 Feb;24(2):442-449. doi: 10.1245/s10434-016-5552-1. Epub 2016 Sep 13.
• [233] Differential expression of PIWIL2 in papillary thyroid cancers.Gene. 2018 Apr 5;649:8-13. doi: 10.1016/j.gene.2018.01.066. Epub 2018 Jan 31.
• [234] The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population.Thyroid. 2015 Mar;25(3):333-40. doi: 10.1089/thy.2014.0431. Epub 2015 Feb 5.
• [235] Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.Pathol Res Pract. 2014 Nov;210(11):733-8. doi: 10.1016/j.prp.2014.06.025. Epub 2014 Jul 16.
• [236] PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.Int J Oncol. 2014 Feb;44(2):548-56. doi: 10.3892/ijo.2013.2208. Epub 2013 Dec 5.
• [237] Expression of the NOB1 gene and its clinical significance in papillary thyroid carcinoma.J Int Med Res. 2013 Jun;41(3):568-72. doi: 10.1177/0300060513479862. Epub 2013 May 17.
• [238] mRNA expression pattern of retinoic acid and retinoid X nuclear receptor subtypes in human thyroid papillary carcinoma.Oncol Rep. 2013 Nov;30(5):2371-8. doi: 10.3892/or.2013.2670. Epub 2013 Aug 20.
• [239] Loss of Rap1GAP in papillary thyroid cancer.J Clin Endocrinol Metab. 2009 Mar;94(3):1026-32. doi: 10.1210/jc.2008-1042. Epub 2008 Dec 9.
• [240] RasGRP3 controls cell proliferation and migration in papillary thyroid cancer by regulating the Akt-MDM2 pathway.Gene. 2017 Oct 30;633:35-41. doi: 10.1016/j.gene.2017.08.024. Epub 2017 Aug 31.
• [241] Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E).Oncotarget. 2017 Sep 24;8(49):84743-84760. doi: 10.18632/oncotarget.21262. eCollection 2017 Oct 17.
• [242] Immunohistochemical expression of RBP2 and LSD1 in papillary thyroid carcinoma.Rom J Morphol Embryol. 2013;54(3):499-503.
• [243] Expression of autophagy-associated proteins in papillary thyroid carcinoma.Oncol Lett. 2017 Jul;14(1):411-415. doi: 10.3892/ol.2017.6101. Epub 2017 Apr 28.
• [244] Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.Cell Mol Biol (Noisy-le-grand). 2005 Sep 5;51(2):177-86.
• [245] Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.Cell Mol Life Sci. 2003 Jul;60(7):1449-59. doi: 10.1007/s00018-003-2381-8.
• [246] Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.Cancer. 2010 Jun 15;116(12):2974-83. doi: 10.1002/cncr.25061.
• [247] Gene expression in papillary thyroid carcinoma reveals highly consistent profiles.Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9. doi: 10.1073/pnas.251547398.
• [248] Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis.Eur J Endocrinol. 2013 Nov 22;170(1):1-12. doi: 10.1530/EJE-13-0623. Print 2014 Jan.
• [249] Common single nucleotide polymorphisms in genes related to immune function and risk of papillary thyroid cancer.PLoS One. 2013;8(3):e57243. doi: 10.1371/journal.pone.0057243. Epub 2013 Mar 8.
• [250] Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer.Dis Markers. 2017;2017:4962137. doi: 10.1155/2017/4962137. Epub 2017 Jan 31.
• [251] Expression of Spindle and Kinetochore-Associated Protein 1 Is Associated with Poor Prognosis in Papillary Thyroid Carcinoma.Dis Markers. 2015;2015:616541. doi: 10.1155/2015/616541. Epub 2015 May 4.
• [252] Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor- type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.Cancer Sci. 2018 Mar;109(3):642-655. doi: 10.1111/cas.13478. Epub 2018 Feb 1.
• [253] A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition.Sci Rep. 2015 Jul 2;5:10566. doi: 10.1038/srep10566.
• [254] An epistatic interaction between the PAX8 and STK17B genes in papillary thyroid cancer susceptibility.PLoS One. 2013 Sep 23;8(9):e74765. doi: 10.1371/journal.pone.0074765. eCollection 2013.
• [255] MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.Tumour Biol. 2016 Jun;37(6):7633-44. doi: 10.1007/s13277-015-4653-y. Epub 2015 Dec 19.
• [256] Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
• [257] A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression.Surgery. 2005 Dec;138(6):1050-6; discussion 1056-7. doi: 10.1016/j.surg.2005.09.010.
• [258] Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/-catenin signaling pathway.Biomed Pharmacother. 2017 Dec;96:98-103. doi: 10.1016/j.biopha.2017.09.132. Epub 2017 Sep 29.
• [259] Suppression of CCT3 inhibits malignant proliferation of human papillary thyroid carcinoma cell.Oncol Lett. 2018 Jun;15(6):9202-9208. doi: 10.3892/ol.2018.8496. Epub 2018 Apr 13.
• [260] Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma.Sci Rep. 2018 Jul 2;8(1):9912. doi: 10.1038/s41598-018-28299-9.
• [261] Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.Sci Rep. 2017 Feb 9;7:42074. doi: 10.1038/srep42074.
• [262] Overexpression of LASS2 inhibits proliferation and causes G0/G1 cell cycle arrest in papillary thyroid cancer.Cancer Cell Int. 2018 Oct 1;18:151. doi: 10.1186/s12935-018-0649-1. eCollection 2018.
• [263] DNA copy number gain-mediated lncRNA LINC01061 upregulation predicts poor prognosis and promotes papillary thyroid cancer progression.Biochem Biophys Res Commun. 2018 Sep 10;503(3):1247-1253. doi: 10.1016/j.bbrc.2018.07.032. Epub 2018 Jul 11.
• [264] E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle.J Exp Clin Cancer Res. 2017 Mar 7;36(1):40. doi: 10.1186/s13046-017-0504-6.
• [265] Overexpression of G Protein-Coupled Receptor Kinase 6 (GRK6) Is Associated with Progression and Poor Prognosis of Papillary Thyroid Carcinoma.Med Sci Monit. 2018 May 28;24:3540-3548. doi: 10.12659/MSM.908176.
• [266] Long Noncoding RNA AB074169 Inhibits Cell Proliferation via Modulation of KHSRP-Mediated CDKN1a Expression in Papillary Thyroid Carcinoma.Cancer Res. 2018 Aug 1;78(15):4163-4174. doi: 10.1158/0008-5472.CAN-17-3766. Epub 2018 May 7.
• [267] Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.Thyroid. 2018 Jun;28(6):748-754. doi: 10.1089/thy.2017.0258. Epub 2018 May 16.
• [268] MiR-129 regulates growth and invasion by targeting MAL2 in papillary thyroid carcinoma.Biomed Pharmacother. 2018 Sep;105:1072-1078. doi: 10.1016/j.biopha.2018.06.050. Epub 2018 Jun 19.
• [269] Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.Endocr J. 2018 Sep 27;65(9):963-967. doi: 10.1507/endocrj.EJ18-0074. Epub 2018 Jun 22.
• [270] RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer.Cell Physiol Biochem. 2017;41(3):1229-1239. doi: 10.1159/000464386. Epub 2017 Mar 7.
• [271] Extracellular Superoxide Dismutase Expression in Papillary Thyroid Cancer Mesenchymal Stem/Stromal Cells Modulates Cancer Cell Growth and Migration.Sci Rep. 2017 Feb 20;7:41416. doi: 10.1038/srep41416.
• [272] Genetic variations in TAS2R3 and TAS2R4 bitterness receptors modify papillary carcinoma risk and thyroid function in Korean females.Sci Rep. 2018 Oct 9;8(1):15004. doi: 10.1038/s41598-018-33338-6.
• [273] Circular RNA circZFR contributes to papillary thyroid cancer cell proliferation and invasion by sponging miR-1261 and facilitating C8orf4 expression.Biochem Biophys Res Commun. 2018 Sep 3;503(1):56-61. doi: 10.1016/j.bbrc.2018.05.174. Epub 2018 Jun 8.
• [274] Long Non-coding Antisense RNA TNRC6C-AS1 Is Activated in Papillary Thyroid Cancer and Promotes Cancer Progression by Suppressing TNRC6C Expression.Front Endocrinol (Lausanne). 2018 Jul 9;9:360. doi: 10.3389/fendo.2018.00360. eCollection 2018.
• [275] miR-182 promotes tumor growth and increases chemoresistance of human anaplastic thyroid cancer by targeting tripartite motif 8.Onco Targets Ther. 2017 Feb 24;10:1115-1122. doi: 10.2147/OTT.S110468. eCollection 2017.
• [276] Molecular Analysis by Gene Expression of Mitochondrial ATPase Subunits in Papillary Thyroid Cancer: Is ATP5E Transcript a Possible Early Tumor Marker?.Med Sci Monit. 2015 Jun 16;21:1745-51. doi: 10.12659/MSM.893597.
• [277] DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer.Blood Cells Mol Dis. 2013 Mar;50(3):161-5. doi: 10.1016/j.bcmd.2012.10.009. Epub 2012 Nov 17.
• [278] The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias.Cancer Lett. 2015 Feb 28;357(2):535-41. doi: 10.1016/j.canlet.2014.12.010. Epub 2014 Dec 9.
• [279] Increased type 3 deiodinase expression in papillary thyroid carcinoma.Thyroid. 2012 Sep;22(9):897-904. doi: 10.1089/thy.2012.0031. Epub 2012 Jul 23.
• [280] Polybrominated Diphenyl Ethers, Polybrominated Biphenyls, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study.Am J Epidemiol. 2020 Feb 28;189(2):120-132. doi: 10.1093/aje/kwz229.
• [281] Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma.Cancer Manag Res. 2019 Aug 20;11:7845-7855. doi: 10.2147/CMAR.S194344. eCollection 2019.
• [282] BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer.Horm Metab Res. 2019 Jan;51(1):69-75. doi: 10.1055/a-0765-9078. Epub 2018 Nov 5.
• [283] The role of prospero homeobox 1 (PROX1) expression in follicular thyroid carcinoma cells.Oncotarget. 2017 Dec 12;8(69):114136-114155. doi: 10.18632/oncotarget.23167. eCollection 2017 Dec 26.
• [284] RTN4IP1 is down-regulated in thyroid cancer and has tumor-suppressive function.J Clin Endocrinol Metab. 2013 Mar;98(3):E446-54. doi: 10.1210/jc.2012-3180. Epub 2013 Feb 7.
• [285] Role of BRAF in thyroid oncogenesis.Clin Cancer Res. 2011 Dec 15;17(24):7511-7. doi: 10.1158/1078-0432.CCR-11-1155. Epub 2011 Sep 7.
• [286] Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.Chin Med J (Engl). 2012 Oct;125(19):3526-31.
• [287] Replication and Meta-Analysis of Common Gene Mutations in TTF1 and TTF2 with Papillary Thyroid Cancer.Medicine (Baltimore). 2015 Sep;94(36):e1246. doi: 10.1097/MD.0000000000001246.
• [288] Cytogenetic and molecular events in adenoma and well-differentiated thyroid follicular-cell neoplasia.Cancer Genet Cytogenet. 2010 Nov;203(1):21-9. doi: 10.1016/j.cancergencyto.2010.08.025.
• [289] miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3/Snail signaling by targeting ARFGEF1.Cell Death Dis. 2019 Feb 27;10(3):195. doi: 10.1038/s41419-019-1444-1.
• [290] Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.J Biol Chem. 2007 May 25;282(21):15490-7. doi: 10.1074/jbc.M610586200. Epub 2007 Apr 4.
• [291] SCF(-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.J Exp Med. 2012 Jul 2;209(7):1289-307. doi: 10.1084/jem.20112446. Epub 2012 Jun 18.
• [292] BRAFV600E mutation, TIMP-1 upregulation, and NF-B activation: closing the loop on the papillary thyroid cancer trilogy.Endocr Relat Cancer. 2011 Nov 14;18(6):669-85. doi: 10.1530/ERC-11-0076. Print 2011 Dec.
• [293] CDC23 regulates cancer cell phenotype and is overexpressed in papillary thyroid cancer.Endocr Relat Cancer. 2011 Nov 28;18(6):731-42. doi: 10.1530/ERC-11-0181. Print 2011.
• [294] CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis.BMC Cancer. 2008 Sep 30;8:274. doi: 10.1186/1471-2407-8-274.
• [295] Correlations between the expression levels of micro-RNA146b, 221, 222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers.Exp Clin Endocrinol Diabetes. 2014 Mar;122(3):137-43. doi: 10.1055/s-0034-1367025. Epub 2014 Mar 18.
• [296] Significance of expression of suppressor of cytokine signaling proteins: Suppressor of cytokine signaling-1, suppressor of cytokine signaling-2, and suppressor of cytokine signaling-3 in papillary thyroid cancer.J Cancer Res Ther. 2017 Apr-Jun;13(2):337-345. doi: 10.4103/0973-1482.174172.
• [297] CITED1 contributes to the progression of papillary thyroid carcinoma via the Wnt/-catenin signaling pathway.Onco Targets Ther. 2019 Aug 21;12:6769-6777. doi: 10.2147/OTT.S215025. eCollection 2019.
• [298] Identification of key genes and miRNAs markers of papillary thyroid cancer.Biol Res. 2018 Nov 10;51(1):45. doi: 10.1186/s40659-018-0188-1.
• [299] CLDN10 is Associated with Papillary Thyroid Cancer Progression.J Cancer. 2018 Nov 25;9(24):4712-4717. doi: 10.7150/jca.28636. eCollection 2018.
• [300] Integration of a radiation biomarker into modeling of thyroid carcinogenesis and post-Chernobyl risk assessment.Carcinogenesis. 2016 Dec;37(12):1152-1160. doi: 10.1093/carcin/bgw102. Epub 2016 Oct 11.
• [301] Negative Expression of CPSF2 Predicts a Poorer Clinical Outcome in Patients with Papillary Thyroid Carcinoma.Thyroid. 2015 Sep;25(9):1020-5. doi: 10.1089/thy.2015.0079. Epub 2015 Aug 3.
• [302] TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma.Head Neck. 2004 Dec;26(12):1069-83. doi: 10.1002/hed.20099.
• [303] CUX2 functions as an oncogene in papillary thyroid cancer.Onco Targets Ther. 2018 Dec 24;12:217-224. doi: 10.2147/OTT.S185710. eCollection 2019.
• [304] Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection.J Transl Med. 2013 Jan 7;11:6. doi: 10.1186/1479-5876-11-6.
• [305] Methylation of DACT2 promotes papillary thyroid cancer metastasis by activating Wnt signaling.PLoS One. 2014 Nov 6;9(11):e112336. doi: 10.1371/journal.pone.0112336. eCollection 2014.
• [306] MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3421-3430. doi: 10.26355/eurrev_201904_17706.
• [307] Dermatopontin inhibits papillary thyroid cancer cell proliferation through MYC repression.Mol Cell Endocrinol. 2019 Jan 15;480:122-132. doi: 10.1016/j.mce.2018.10.021. Epub 2018 Nov 2.
• [308] BRAF-Oncogene-Induced Senescence and the Role of Thyroid-Stimulating Hormone Signaling in the Progression of Papillary Thyroid Carcinoma.Horm Cancer. 2018 Feb;9(1):1-11. doi: 10.1007/s12672-017-0315-4. Epub 2017 Dec 5.
• [309] MassARRAY-based simultaneous detection of hotspot somatic mutations and recurrent fusion genes in papillary thyroid carcinoma: the PTC-MA assay.Endocrine. 2018 Jul;61(1):36-41. doi: 10.1007/s12020-017-1483-2. Epub 2017 Dec 6.
• [310] E26 transformation (ETS)specific related transcription factor? (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.Oncol Rep. 2019 Jan;41(1):570-578. doi: 10.3892/or.2018.6807. Epub 2018 Oct 18.
• [311] Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.Thyroid. 2005 Apr;15(4):326-35. doi: 10.1089/thy.2005.15.326.
• [312] The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells.Neoplasia. 2018 Nov;20(11):1121-1134. doi: 10.1016/j.neo.2018.09.003. Epub 2018 Sep 25.
• [313] The Highly Expressed FAM83F Protein in Papillary Thyroid Cancer Exerts a Pro-Oncogenic Role in Thyroid Follicular Cells.Front Endocrinol (Lausanne). 2019 Mar 1;10:134. doi: 10.3389/fendo.2019.00134. eCollection 2019.
• [314] FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/-catenin pathway.J Cell Physiol. 2019 Aug;234(10):17739-17748. doi: 10.1002/jcp.28399. Epub 2019 Feb 22.
• [315] Inhibition of Nrf2 promotes the antitumor effect of Pinelliae rhizome in papillary thyroid cancer.J Cell Physiol. 2019 Aug;234(8):13867-13877. doi: 10.1002/jcp.28069. Epub 2019 Jan 30.
• [316] MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.Biochem Biophys Res Commun. 2013 Nov 29;441(4):958-63. doi: 10.1016/j.bbrc.2013.11.010. Epub 2013 Nov 9.
• [317] GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland.Thyroid. 2019 Feb;29(2):161-173. doi: 10.1089/thy.2018.0791.
• [318] Epigenetic silencing of HOPX is critically involved in aggressive phenotypes and patient prognosis in papillary thyroid cancer.Oncotarget. 2019 Oct 15;10(57):5906-5918. doi: 10.18632/oncotarget.27187. eCollection 2019 Oct 15.
• [319] LncRNA HOXA-AS2 Facilitates Tumorigenesis and Progression of Papillary Thyroid Cancer by Modulating the miR-15a-5p/HOXA3 Axis.Hum Gene Ther. 2019 May;30(5):618-631. doi: 10.1089/hum.2018.109. Epub 2019 Feb 26.
• [320] MYC promotes the development of papillary thyroid carcinoma by inhibiting the expression of lncRNA PAX8AS1:28.Oncol Rep. 2019 Apr;41(4):2511-2517. doi: 10.3892/or.2019.6996. Epub 2019 Feb 1.
• [321] MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways.J Cell Physiol. 2019 Aug;234(10):18382-18391. doi: 10.1002/jcp.28472. Epub 2019 Apr 2.
• [322] Characterisation of DEHAL1 expression in thyroid pathologies.Eur J Endocrinol. 2007 Mar;156(3):295-301. doi: 10.1530/EJE-06-0596.
• [323] Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.Exp Mol Pathol. 2018 Aug;105(1):153-159. doi: 10.1016/j.yexmp.2018.07.006. Epub 2018 Jul 19.
• [324] RET fusions in solid tumors.Cancer Treat Rev. 2019 Dec;81:101911. doi: 10.1016/j.ctrv.2019.101911. Epub 2019 Oct 30.
• [325] Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma.Cancer Biomark. 2019;24(1):71-83. doi: 10.3233/CBM-181758.
• [326] Lipase member H is a downstream molecular target of hypoxia inducible factor-1 and promotes papillary thyroid carcinoma cell migration in BCPAP and KTC-1 cell lines.Cancer Manag Res. 2019 Jan 22;11:931-941. doi: 10.2147/CMAR.S183355. eCollection 2019.
• [327] Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression.Cell Death Dis. 2019 Feb 22;10(3):184. doi: 10.1038/s41419-019-1439-y.
• [328] MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr Relat Cancer. 2016 Apr;23(4):335-47. doi: 10.1530/ERC-15-0322. Epub 2016 Feb 24.
• [329] Low metallothionein 1M (MT1M) is associated with thyroid cancer cell lines progression.Am J Transl Res. 2019 Mar 15;11(3):1760-1770. eCollection 2019.
• [330] Human herpes simplex viruses in benign and malignant thyroid tumours.J Pathol. 2010 Jun;221(2):193-200. doi: 10.1002/path.2701.
• [331] MicroRNA?44 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1.Mol Med Rep. 2019 Mar;19(3):1903-1910. doi: 10.3892/mmr.2019.9826. Epub 2019 Jan 4.
• [332] Two-dimensional complementary deoxyribonucleic acid electrophoresis revealing up-regulated human epididymal protein-1 and down-regulated CL-100 in thyroid papillary carcinoma.Endocrinology. 2002 Nov;143(11):4422-8. doi: 10.1210/en.2002-220550.
• [333] Positive Feedback Loops Between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.J Clin Endocrinol Metab. 2017 Feb 1;102(2):613-624. doi: 10.1210/jc.2016-1677.
• [334] High expression of NUCB2 promotes papillary thyroid cancer cells proliferation and invasion.Onco Targets Ther. 2019 Feb 18;12:1309-1318. doi: 10.2147/OTT.S184560. eCollection 2019.
• [335] CITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27.Cell Biosci. 2018 Nov 6;8:57. doi: 10.1186/s13578-018-0256-9. eCollection 2018.
• [336] Reprogramming of Energy Metabolism: Increased Expression and Roles of Pyruvate Carboxylase in Papillary Thyroid Cancer.Thyroid. 2019 Jun;29(6):845-857. doi: 10.1089/thy.2018.0435.
• [337] RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma.Oncogene. 2000 Aug 31;19(37):4236-42. doi: 10.1038/sj.onc.1203772.
• [338] Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma.Oncotarget. 2017 Aug 24;8(44):77453-77464. doi: 10.18632/oncotarget.20512. eCollection 2017 Sep 29.
• [339] PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ER/ER protein ratio.Sci Rep. 2019 Jan 31;9(1):1032. doi: 10.1038/s41598-018-37648-7.
• [340] Expression of the ring ligase PRAJA2 in thyroid cancer.J Clin Endocrinol Metab. 2012 Nov;97(11):4253-9. doi: 10.1210/jc.2012-2360. Epub 2012 Sep 4.
• [341] Immune cell infiltrate-associated dysregulation of DNA repair machinery may predispose to papillary thyroid carcinogenesis.Surgery. 2020 Jan;167(1):66-72. doi: 10.1016/j.surg.2019.02.024. Epub 2019 Aug 19.
• [342] The POLR2E rs3787016 polymorphism is strongly associated with the risk of female breast and cervical cancer.Pathol Res Pract. 2019 May;215(5):1061-1065. doi: 10.1016/j.prp.2019.02.015. Epub 2019 Feb 27.
• [343] Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.Thyroid. 2011 Apr;21(4):391-9. doi: 10.1089/thy.2010.0168.
• [344] Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma.Eur J Endocrinol. 2012 Jun;166(6):1049-60. doi: 10.1530/EJE-12-0144. Epub 2012 Mar 28.
• [345] RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.J Endocrinol Invest. 2008 Oct;31(10):893-9. doi: 10.1007/BF03346438.
• [346] CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway.Cancer Lett. 2020 Jan 28;469:68-77. doi: 10.1016/j.canlet.2019.10.017. Epub 2019 Oct 17.
• [347] Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer.J Clin Endocrinol Metab. 2014 Jul;99(7):E1316-21. doi: 10.1210/jc.2014-1225. Epub 2014 Apr 8.
• [348] Novel rearrangements involving the RET gene in papillary thyroid carcinoma.Cancer Genet. 2019 Jan;230:13-20. doi: 10.1016/j.cancergen.2018.11.002. Epub 2018 Nov 13.
• [349] Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.PLoS One. 2010 Sep 22;5(9):e12701. doi: 10.1371/journal.pone.0012701.
• [350] HGF-mediated S100A11 overexpression enhances proliferation and invasion of gastric cancer.Am J Transl Res. 2018 Nov 15;10(11):3385-3394. eCollection 2018.
• [351] MicroRNA-1270 modulates papillary thyroid cancer cell development by regulating SCAI.Biomed Pharmacother. 2019 Jan;109:2357-2364. doi: 10.1016/j.biopha.2018.08.150. Epub 2018 Nov 30.
• [352] Diagnostic usefulness of PCR profiling of the differentially expressed marker genes in thyroid papillary carcinomas.Cancer Lett. 2005 Jun 28;224(2):289-301. doi: 10.1016/j.canlet.2004.10.012. Epub 2004 Nov 18.
• [353] SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.Oncogene. 2019 Jan;38(3):345-359. doi: 10.1038/s41388-018-0434-6. Epub 2018 Aug 9.
• [354] miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1.Biochem Biophys Res Commun. 2018 Feb 26;497(1):181-186. doi: 10.1016/j.bbrc.2018.02.051. Epub 2018 Feb 8.
• [355] SOX11 expression in a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma containing BRAF c.1799_1801delTGA and CTNNB1 c.133T>C mutations.Virchows Arch. 2019 Oct;475(4):519-525. doi: 10.1007/s00428-019-02619-4. Epub 2019 Jul 20.
• [356] NR2F1-AS1 regulated miR-423-5p/SOX12 to promote proliferation and invasion of papillary thyroid carcinoma.J Cell Biochem. 2020 Feb;121(2):2009-2018. doi: 10.1002/jcb.29435. Epub 2019 Nov 6.
• [357] Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.Histochem Cell Biol. 2018 Jun;149(6):635-644. doi: 10.1007/s00418-018-1660-2. Epub 2018 Mar 12.
• [358] The expression and role of serum response factor in papillary carcinoma of the thyroid.Int J Oncol. 2009 Jul;35(1):49-55.
• [359] SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab. 2013 May;98(5):E973-80. doi: 10.1210/jc.2012-3823. Epub 2013 Mar 28.
• [360] miR-199b-5p-Stonin 2 axis regulates metastases and epithelial-to-mesenchymal transition of papillary thyroid carcinoma.IUBMB Life. 2019 Jan;71(1):28-40. doi: 10.1002/iub.1889. Epub 2018 Oct 16.
• [361] MiR-758-3p regulates papillary thyroid cancer cell proliferation and migration by targeting TAB1.Pharmazie. 2019 Apr 1;74(4):235-238. doi: 10.1691/ph.2019.8933.
• [362] MicroRNA-486 inhibits cell proliferation, invasion and migration via down-regulating the TENM1 expressions and affecting ERK and Akt signaling pathways and epithelial-to-mesenchymal transition in papillary thyroid carcinoma.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8429-8439. doi: 10.26355/eurrev_201910_19155.
• [363] Lentivirus-mediated shRNA interference of trefoil factor 3 blocks cell viability, migration and invasion in the papillary thyroid carcinoma cells.Neoplasma. 2018;65(2):169-177. doi: 10.4149/neo_2018_170119N51.
• [364] Rearrangements of NTRK1 gene in papillary thyroid carcinoma.Mol Cell Endocrinol. 2010 May 28;321(1):44-9. doi: 10.1016/j.mce.2009.10.009. Epub 2009 Oct 31.
• [365] Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer.Clin Otolaryngol. 2020 Jan;45(1):55-62. doi: 10.1111/coa.13466. Epub 2019 Nov 13.
• [366] The Association of BRAF V600E Mutation With Tissue Inhibitor of Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer.Int J Endocrinol Metab. 2018 Feb 10;16(2):e56120. doi: 10.5812/ijem.56120. eCollection 2018 Apr.
• [367] Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.J Surg Res. 2014 Dec;192(2):487-93. doi: 10.1016/j.jss.2014.05.066. Epub 2014 May 27.
• [368] Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29.
• [369] NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.Cancer. 2016 Apr 1;122(7):1097-107. doi: 10.1002/cncr.29887. Epub 2016 Jan 19.
• [370] Tripartite motif containing 14: An oncogene in papillary thyroid carcinoma.Biochem Biophys Res Commun. 2020 Jan 8;521(2):360-367. doi: 10.1016/j.bbrc.2019.10.127. Epub 2019 Oct 24.
• [371] Overexpression of TRIM26 suppresses the proliferation, metastasis, and glycolysis in papillary thyroid carcinoma cells.J Cell Physiol. 2019 Aug;234(10):19019-19027. doi: 10.1002/jcp.28541. Epub 2019 Mar 29.
• [372] Downregulation of TSPAN13 by miR-369-3p inhibits cell proliferation in papillary thyroid cancer (PTC).Bosn J Basic Med Sci. 2019 May 20;19(2):146-154. doi: 10.17305/bjbms.2018.2865.
• [373] Expression of serum AMPD1 in thyroid carcinoma and its clinical significance.Exp Ther Med. 2018 Apr;15(4):3357-3361. doi: 10.3892/etm.2018.5859. Epub 2018 Feb 12.
• [374] ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma.Cancer Genet. 2019 Oct;238:10-17. doi: 10.1016/j.cancergen.2019.07.002. Epub 2019 Jul 5.
• [375] AP-2 expression in papillary thyroid carcinoma predicts tumor progression and poor prognosis.Cancer Manag Res. 2018 Aug 13;10:2615-2625. doi: 10.2147/CMAR.S167874. eCollection 2018.
• [376] Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.Endocr Pathol. 2019 Dec;30(4):262-269. doi: 10.1007/s12022-019-09589-y.
• [377] Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer.Endocrine. 2019 Dec;66(3):573-584. doi: 10.1007/s12020-019-02021-9. Epub 2019 Jul 22.
• [378] BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients.Onco Targets Ther. 2019 Aug 28;12:6937-6945. doi: 10.2147/OTT.S219506. eCollection 2019.
• [379] Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.Oncol Lett. 2018 Apr;15(4):4269-4277. doi: 10.3892/ol.2018.7873. Epub 2018 Jan 26.
• [380] Serum deprivation response functions as a tumor suppressor gene in papillary thyroid cancer.Clin Genet. 2019 Nov;96(5):418-428. doi: 10.1111/cge.13609. Epub 2019 Jul 31.
• [381] MicroRNA-23a inhibits the growth of papillary thyroid carcinoma via regulating cyclin G1.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3431-3439. doi: 10.26355/eurrev_201904_17707.
• [382] KIAA1199, a Target of MicoRNA-486-5p, Promotes Papillary Thyroid Cancer Invasion by Influencing Epithelial-Mesenchymal Transition (EMT).Med Sci Monit. 2019 Sep 10;25:6788-6796. doi: 10.12659/MSM.918682.
• [383] Preliminary screening and analysis of metastasis-related lncRNA and co-expressed papillary thyroid carcinoma mRNA.Oncol Lett. 2018 Sep;16(3):3715-3725. doi: 10.3892/ol.2018.9080. Epub 2018 Jul 5.
• [384] Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/-catenin signaling and sensitizes cancer cells to FH535 therapy.Cancer Med. 2018 Feb;7(2):285-296. doi: 10.1002/cam4.1272. Epub 2018 Jan 17.
• [385] CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of -catenin pathway.J Exp Clin Cancer Res. 2018 Nov 13;37(1):275. doi: 10.1186/s13046-018-0936-7.
• [386] Linc01278 inhibits the development of papillary thyroid carcinoma by regulating miR-376c-3p/DNM3 axis.Cancer Manag Res. 2019 Sep 19;11:8557-8569. doi: 10.2147/CMAR.S217886. eCollection 2019.
• [387] Association between Genetic Polymorphisms in microRNA Machinery Genes and Risk of Papillary Thyroid Carcinoma.Pathol Oncol Res. 2020 Apr;26(2):1235-1241. doi: 10.1007/s12253-019-00688-z. Epub 2019 Jun 27.
• [388] MicroRNA-30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7.Exp Ther Med. 2019 Jul;18(1):209-215. doi: 10.3892/etm.2019.7532. Epub 2019 Apr 30.
• [389] Eps15 homology domain 1 promotes the evolution of papillary thyroid cancer by regulating endocytotic recycling of epidermal growth factor receptor.Oncol Lett. 2018 Oct;16(4):4263-4270. doi: 10.3892/ol.2018.9200. Epub 2018 Jul 24.
• [390] Prediction of the Prognosis Based on Chromosomal Instability-Related DNA Methylation Patterns of ELOVL2 and UBAC2 in PTCs.Mol Ther Nucleic Acids. 2019 Dec 6;18:650-660. doi: 10.1016/j.omtn.2019.09.027. Epub 2019 Oct 7.
• [391] The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer.PLoS One. 2018 Dec 21;13(12):e0209338. doi: 10.1371/journal.pone.0209338. eCollection 2018.
• [392] Identification of potential functional genes in papillary thyroid cancer by co-expression network analysis.Oncol Lett. 2018 Oct;16(4):4871-4878. doi: 10.3892/ol.2018.9306. Epub 2018 Aug 14.
• [393] Serum-based metabolic alterations in patients with papillary thyroid carcinoma unveiled by non-targeted 1H-NMR metabolomics approach.Iran J Basic Med Sci. 2018 Nov;21(11):1140-1147. doi: 10.22038/IJBMS.2018.30375.7323.
• [394] The association between irisin and muscle metabolism in different thyroid disorders.Clin Endocrinol (Oxf). 2018 Mar;88(3):460-467. doi: 10.1111/cen.13527. Epub 2017 Dec 20.
• [395] Bioinformatic analysis of the prognostic value and potential regulatory network of FOXF1 in papillary thyroid cancer.Biofactors. 2019 Nov;45(6):902-911. doi: 10.1002/biof.1561. Epub 2019 Sep 9.
• [396] Hsa_circ_0058124 promotes papillary thyroid cancer tumorigenesis and invasiveness through the NOTCH3/GATAD2A axis.J Exp Clin Cancer Res. 2019 Jul 19;38(1):318. doi: 10.1186/s13046-019-1321-x.
• [397] Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.Biomed Pharmacother. 2019 Aug;116:108966. doi: 10.1016/j.biopha.2019.108966. Epub 2019 May 16.
• [398] Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.Oncol Rep. 2018 Jan;39(1):338-348. doi: 10.3892/or.2017.6058. Epub 2017 Oct 25.
• [399] Down-regulated HSDL2 expression suppresses cell proliferation and promotes apoptosis in papillary thyroid carcinoma.Biosci Rep. 2019 Jun 4;39(6):BSR20190425. doi: 10.1042/BSR20190425. Print 2019 Jun 28.
• [400] Impact factors for the outcome of the first (131)I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy.Ann Nucl Med. 2019 Mar;33(3):177-183. doi: 10.1007/s12149-018-01321-w. Epub 2018 Dec 4.
• [401] Underexpression of INPPL1 is associated with aggressive clinicopathologic characteristics in papillary thyroid carcinoma.Onco Targets Ther. 2018 Nov 1;11:7725-7731. doi: 10.2147/OTT.S185803. eCollection 2018.
• [402] The Profile of Genetic Mutations in Papillary Thyroid Cancer Detected by Whole Exome Sequencing.Cell Physiol Biochem. 2018;50(1):169-178. doi: 10.1159/000493966. Epub 2018 Oct 2.
• [403] JAZF1 Suppresses Papillary Thyroid Carcinoma Cell Proliferation and Facilitates Apoptosis via Regulating TAK1/NF-B Pathways.Onco Targets Ther. 2019 Dec 2;12:10501-10514. doi: 10.2147/OTT.S230597. eCollection 2019.
• [404] LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.Mol Med Rep. 2018 Jun;17(6):7521-7528. doi: 10.3892/mmr.2018.8856. Epub 2018 Apr 5.
• [405] LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.Endocr Pathol. 2018 Sep;29(3):222-230. doi: 10.1007/s12022-018-9526-7.
• [406] LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.Int J Oncol. 2018 Apr;52(4):1189-1197. doi: 10.3892/ijo.2018.4273. Epub 2018 Feb 9.
• [407] MKL1 overexpression predicts poor prognosis in patients with papillary thyroid cancer and promotes nodal metastasis.J Cell Sci. 2019 Aug 22;132(16):jcs231399. doi: 10.1242/jcs.231399.
• [408] In-Depth Proteomics Analysis to Identify Biomarkers of Papillary Thyroid Cancer Patients Older Than 45 Years with Different Degrees of Lymph Node Metastases.Proteomics Clin Appl. 2019 Sep;13(5):e1900030. doi: 10.1002/prca.201900030. Epub 2019 Jun 7.
• [409] miR-29a-3p inhibits growth, proliferation, and invasion of papillary thyroid carcinoma by suppressing NF-B signaling via direct targeting of OTUB2.Cancer Manag Res. 2018 Dec 17;11:13-23. doi: 10.2147/CMAR.S184781. eCollection 2019.
• [410] Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.Pathol Oncol Res. 2020 Jul;26(3):1833-1841. doi: 10.1007/s12253-019-00779-x. Epub 2019 Nov 22.
• [411] Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer.Nat Commun. 2017 Jul 13;8:15966. doi: 10.1038/ncomms15966.
• [412] Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression.Oncol Lett. 2019 Sep;18(3):3227-3235. doi: 10.3892/ol.2019.10632. Epub 2019 Jul 18.
• [413] MiR-4500 Regulates PLXNC1 and Inhibits Papillary Thyroid Cancer Progression.Horm Cancer. 2019 Dec;10(4-6):150-160. doi: 10.1007/s12672-019-00366-1. Epub 2019 Jul 17.
• [414] REG Is Associated with Lymph Node Metastasis and T-Stage in Papillary Thyroid Carcinoma.Med Sci Monit. 2018 Mar 6;24:1373-1378. doi: 10.12659/msm.905664.
• [415] RRS1 gene expression involved in the progression of papillary thyroid carcinoma.Cancer Cell Int. 2018 Feb 13;18:20. doi: 10.1186/s12935-018-0519-x. eCollection 2018.
• [416] Identification of differentiated functional modules in papillary thyroid carcinoma by analyzing differential networks.J Cancer Res Ther. 2018 Dec;14(Supplement):S969-S974. doi: 10.4103/jcrt.JCRT_730_16.
• [417] SDC4 Gene Silencing Favors Human Papillary Thyroid Carcinoma Cell Apoptosis and Inhibits Epithelial Mesenchymal Transition via Wnt/-Catenin Pathway.Mol Cells. 2018 Sep 30;41(9):853-867. doi: 10.14348/molcells.2018.0103. Epub 2018 Aug 31.
• [418] ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population.Eur J Endocrinol. 2018 Jan;178(1):83-91. doi: 10.1530/EJE-17-0499. Epub 2017 Oct 18.
• [419] TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57(KIP2) repression.Oncogene. 2018 May;37(21):2773-2792. doi: 10.1038/s41388-017-0090-2. Epub 2018 Mar 7.
• [420] Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma.Biomed Res Int. 2019 Nov 19;2019:1791065. doi: 10.1155/2019/1791065. eCollection 2019.
• [421] TEKT4 Promotes Papillary Thyroid Cancer Cell Proliferation, Colony Formation, and Metastasis through Activating PI3K/Akt Pathway.Endocr Pathol. 2018 Dec;29(4):310-316. doi: 10.1007/s12022-018-9549-0.
• [422] RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.Mod Pathol. 2018 Sep;31(9):1346-1360. doi: 10.1038/s41379-018-0051-5. Epub 2018 Apr 30.
• [423] High-accuracy Detection of Preoperative Thyroid Nodules Using Combination of BRAF(V600E) Mutation and TMPRSS4 mRNA Level.Arch Med Res. 2018 Aug;49(6):365-372. doi: 10.1016/j.arcmed.2018.11.003. Epub 2018 Dec 3.
• [424] TIPE2 acts as a biomarker for tumor aggressiveness and suppresses cell invasiveness in papillary thyroid cancer (PTC).Cell Biosci. 2018 Aug 31;8:49. doi: 10.1186/s13578-018-0247-x. eCollection 2018.
• [425] Altered TEG Parameters Identify Hypercoagulablilty and are of Diagnosis Value for Papillary Thyroid Carcinoma Patients.Exp Clin Endocrinol Diabetes. 2020 May;128(5):297-302. doi: 10.1055/a-0723-3295. Epub 2018 Sep 20.
• [426] LncRNA HOXA11-AS accumulation-induced microRNA-761 downregulation regulates cell growth by targeting TRIM29 in papillary thyroid cancer.Am J Transl Res. 2019 Nov 15;11(11):6826-6837. eCollection 2019.